Promising strategies for obesity pharmacotherapy: Melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists

Current Topics in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 504-538

  Jeon, Moon Kook ^a   Cheon, Hyae Gyeong ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Anti obesity drugs; Energy homeostasis; Melanin concentrating hormone; Melanocortin 4; Weight loss

Indexed keywords

2,4 DINITROPHENOL; 6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; ALIZYME; ANTIOBESITY AGENT; AP 1030; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CBT 01452; CETILISTAT; GW 0071; GW 510516; KD 3010; LG 100641; LORCASERIN; MB 243; MBX 8025; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MIFOBATE; MK 0493; MK 0557; NGD 4715; PIPERAZINE D PHENYLALANINE DERIVATIVE; PIPERIDINE 4 ARYLPYRROLIDINE 3 CARBOXYLIC ACID DERIVATIVE; PIPERIDINE D PHENYLALANINE DERIVATIVE; PSN 821; SB 568849; SIBUTRAMINE; SOBETIROME; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPETITE; BARIATRIC SURGERY; BASAL METABOLIC RATE; BINDING AFFINITY; BODY MASS; CLINICAL TRIAL; DEFECATION URGENCY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENERGY BALANCE; FATTY ACID OXIDATION; FECES INCONTINENCE; FLATULENCE; FOOD INTAKE; HEART MUSCLE FIBROSIS; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID HYDROLYSIS; LIPID METABOLISM; MAXIMUM PLASMA CONCENTRATION; METABOLIC REGULATION; NONHUMAN; OBESITY; OXIDATION; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; STEATORRHEA; STOMACH BYPASS; TACHYCARDIA; THERMOGENESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; OBESITY; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, SOMATOSTATIN;

EID: 68949205198     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788897826     Document Type: Review

References (368)

1. North American Association for the Study of Obesity and the National Heart and Blood Institute. The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults, 2000.
2. Ogden, C.L.; Carroll, M.D.; Curtin, L.R.; McDowell, M.A.; Tabak, C.J.; Flegal, K.M. Prevalence of overweight and obesity in the United States, 1999-2004. J. Am. Med. Assoc. 2006, 295, 1549-1555.
3. Center for Disease Control and Prevention. Overweight and Obesity: U.S. Obesity Trends. Available from: http://www.cdc.gov/obesity/data/ trends.html
4. Hedley, A.A.; Ogden, C.L.; Johnson, C.L.; Carroll, M.D.; Curtin, L.R.; Flegal, K.M. Overweight and obesity among US children adolescents, and adults, 1999-2002. J. Am. Med. Assoc. 2004, 291, 2847-2850.
5. Center for Disease Control and Prevention. Overweight and Obesity: Childhood Overweight and Obesity. Obesity Prevalence. Available from: http://www.cdc.gov/obesity/childhood/prevalence.html
6. Kopelman, P.G. Obesity as a medical problem. Nature 2000, 404, 635-643.
7. World Health Organization. Obesity: Preventing and managing the global epidemic 894, WHO Technical Report Series, Geneva 2000.
8. Food and Drug Administration. Guidance for the clinical evaluation of weight control drugs 1996.
9. Foster, G.D.; Wadden, T.A.; Vogt, R.A.; Brewer, G. What is a reasonable weight loss? Patient's expectations and evaluations of obesity treatment outcomes. J. Consul. Clin. Psychol. 1997, 65, 79-85.
10. Staten, M.A. Challenges in the discovery and development of new agents for the treatment of obesity. Clin. Pharmacol. Ther. 2007, 81, 753-755.
11. Harper, J.A.; Dickinson, K.; Brand, M.D. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes. Rev. 2001, 2, 55-65.
12. Kolanowski, J. A risk-benefit assessment of antiobesity drugs. Drug Saf. 1999, 20, 119-31.
13. Yanovski, S.Z.; Yanovski, J.A. Obesity. N. Engl. J. Med. 2002, 346, 591-602.
14. McNeely, W.; Goa, K.L. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998, 6, 1093-1124.
15. Hvizdos, K.M.; Markham, A. Orlistat. A review of its use in the management of obesity. Drugs 1999, 58, 743-760
16. Foxcrogt, D.R.; Milne, R. Orlistat for the treatment of obesity: Rapid review and cost-effectiveness model. Obes. Rev. 2000, 1, 121-126.
17. Arterburn, D.E.; Crane, P.K.; Veenstra, D.L. The efficacy and safety of sibutramine for weight loss: A systematic review. Arch. Intern. Med. 2004, 164, 994-1003.
18. Finer N. Sibutramine: Its mode of action and efficacy. Int. J. Obes. Relat. Metab. Disord. 2002, 26 (suppl. 4), S29-S33.
19. Matsuda, L.A.; Lolait, S.J.; Brwonstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-564.
20. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
21. Janero, D.R.; Makriyannis, A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience and translational prognosis. Expert Opin Emerg. Drugs 2009, 14, 43-65.
22. DeWald, T.; Khaodhiar, L.; Donahue, M.O.; Blackburn, G. Pharmacological and surgical treatments for obesity. Am. Heart J. 2006, 151, 602-624.
23. Cummings, D.E.; Overduin, J.; Foster-Schubert, K.E. Gastric bypass for obesity: Mechanisms of weight loss and diabetes resolution. J. Clin. Endocrinol. Metab. 2004, 89, 2608-2615.
24. le Roux, C.W.; Aylwin, S.J.; Batterham, R.L.; Borg, C.M.; Coyle, F.; Prasad, V.; Shurey, S.; Ghatei, M.A.; Patel, A.G.; Bloom, S.R. Gut hormine profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg., 2006, 243, 108-114.
25. Gura, T. Obesity drug pipeline not so fat. Science 2003, 299, 849-852.
26. Foster-Schubert, K.E.; Cummings, D.E. Emerging therapeutic strategies for obesity. Endocr. Rev., 2006, 27, 779-793.
27. Harford, J.C.; Haroold, J.A.; Lawton, C.L.; Blundell, J.E. Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets 2005, 6, 201-213.
28. Dunlop, J.; Sabb, A.L.; Mazandarani, H.; Zhang, J.; Kalgaonker, S.; Shukhina, E.; Sukoff, S.; Vogel, R.L.; Stack, G.; Schechter, L.; Harrison, B.L.; Rosenzweig-Lipson, S. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10a-octahydro-7bH-cyclopenta [b][1,4]diazepino [6,7,1hindole], a novel 5-hydroxy-tryptamine 2C receptor-selective agonist with anorectic activity. J. Pharmacol. Exp.Ther. 2005, 313, 862-869.
29. Bivens, C.L.M.; Thomas, W.J.; Stanley, B.G. Similar feeding patterns are induced by perifornical neuropeptide Y injection and by food deprivation. Brain Res 1998, 782, 271-280.
30. Wieland, H.A.; Hamilton, B.S.; Drist, B.; Doods, H.N. The role of NPY in metabolic homeostasis: Implications for obesity therapy. Invest. Drugs, 2000, 9, 1327-1346.
31. Erondu, N.; Gantz, I.; Musser, B.; Suryawanshi, S.; Mallick, M.; Addy, C.; Cote, J.; Bray, G.; Fujioka, K.; Bays, H.; Hollander, P.; Sanabria-Bohorquez, S.M.; Eng, W.; Langstrom, B.; Hargreaves, R.J.; Burns, H.D.; Kanatani, A.; Fukami, T.; MacNeil, D.J.; Gottesdiener, K.M.; Amatruda, J.M.; Kaufman, K.D.; Heymsfield, S.B. Neuropeptide Y5 receptor antagonism dose not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006, 4, 275-82.
32. Henry, B.A.; Clarke, I.J. Adipose tissue hormones and the regulation of food intake. J. Neuroendocrinol. 2008, 20, 842-849.
33. Friedman, J.M.; Halaas, J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395, 763-770.
34. Grasso, P.; Rozhavskaya-Arena, M.; Leinung, M.C.; Lee, D.W. [D-LEU-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice. Regul. Pept. 2001, 101, 123-129.
35. Huszar, D.; Lynch, C.A.; Fairchild-Huntress, V.; Dunmore, J.H.; Fang, Q.; Berkemeier, L.R.; Gu, W.; Kesterson, R.A.; Boston, B.A.; Cone, R.D.; Smith, F.J.; Campfield, L.A.; Burn, P.; Lee, F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88, 131-141.
36. Chen, A.S.; Marsh, D.J.; Trumbauer, M.E.; Frazier, E.G.; Guan, X.M.; Yu, H.; Rosenblum, C.I.; Vongs, A.; Feng, Y.; Cao, L.; Metzger, J.M.; Strack, A.M.; Camacho, R.E.; Mellin, T.N.; Nunes, C.N.; Min, W.; Fisher, J.; Gopal-Truter, S.; MacIntyre, D.E.; Chen, H.Y.; Van der Ploeg, L.H. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 2000, 26, 97-102.
37. Benoit, S.C.; Schwartz, M.W.; Lachey, J.L.; Hagan, M.M.; Rushing, P.A.; Blake, K.A.; Yagaloff, K.A.; Kurylko, G.; Franco, L.; Danhoo, W.; Seeley, R. J. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J. Neurosci., 2000, 20, 3442-3448.
38. Pissios, P.; Bradley, R.L.; Maratos-Flier, E. Expanding the scales: The multiple roles of MCH in regulating energy balance and other biological functions. Endocr. Rev. 2006, 27, 606-620.
39. Collins, C.A.; Kym, P.R. Prospects for obesity treatment: MCH receptor antagonists. Curr. Opin. Invest. Drugs 2003, 4, 386-394.
40. Matthews, V.B., Febbraio, M.A. CNTF: A target therapeutic for obesity-related metabolic disease? J. Mol. Med. 2008, 86, 353-361.
41. Ettinger, M.P.; Littlejohn, T.W.; Schwartz, S.L.; Weiss, S.R.; McIlwain, H.H.; Heymsfield, S.B.; Bray, G.A.; Roberts, W.G.; Heyman, E.R.; Stambler, N.; Heshka, S.; Vicary, C.; Guler, H.P. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults. J. Am. Med. Assoc. 2003, 289, 1826-1832.
42. Bray, G.A. Afferent signals regulating food intake. Proc. Nutr. Sci. 2000, 59, 373-384.
43. Szewczyk, J.R.; Laudeman, C. CCK1R agonists: A promising target for the pharmacological treatment of obesity. Curr. Top. Med. Chem. 2003, 3, 837-854.
44. Padwal, R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr. Opin. Investig. Drugs 2008, 9, 414-421.
45. Cohen, P.; Friedman; J.M. Leptin and the control of metabolism: Role for stearoyl-CoA desaturase-1 (SCD-1). J. Nutr. 2004, 134, 2455S-63.
46. Chen, H.C.; Farese, R.V.J. Inhibition of triglyceride synthesis as a treatment strategy for obesity. Lessons from DGAT1-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 482-486
47. Zabolotny, J.M.; Bence-Hanulec, K.K.; Stricker-Krongrad, A.; Haj, F.; Wang, Y.; Minokoshi, Y.; Kim, Y.B.; Elmquisy, J.K.; Tartaglia, L.A.; Kahn, B.B.; Neel, B.G. PTP-1B regulated leptin signal transduction in vivo. Dev. Cell 2002, 2, 489-495.
48. Mayo, K.E.; Miller, L.J.; Bataille, D.; Dalle, S.; Goke, B.; Thorens, B.; Drucker, D.J. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 2003, 55, 167-194.
49. DeFronzo, R.A.; Ratner, R.E.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28, 1092-1100.
50. Adrian, T.E.; Ferri, G.L.; Bacarese-Hamilton, A.J.; Fuessl, H.S.; Polak, J.M.; Bloom, S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89, 1070-1077.
51. Batterham, R.L.; Cowley, M.A.; Small, C.J.; Herzog, H.; Cohen, M.A.; Dakin, C.L.; Wren, A.M.; Brynes, A.E.; Low, M.J.; Ghatei, M.A.; Cone, R.D.; Bloom, S.R. Gut hormone PYY 3-36 physiologically inhibits food intake. Nature 2002, 418, 650-653.
52. McGowan, B.M.; Bloom, S.R. Peptide YY and appetite control. Curr. Opin. Pharmacol. 2004, 4, 583-588.
53. Hu, B.; Jennings, L.L. Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type 2 diabetes mellitus. Prog. Med. Chem. 2003, 41, 167-194.
54. Weyer, C.; Gautier, J.F.; Danforth, E.Jr. Development of β3-adrenoceptor agonists for the treatment of obesity-an update. Diabetes Metab. 1999, 25, 11-21.
55. Ribeiro, R.C.; Kushner, P.J.; Baxter, J.D. The nuclear hormone receptor gene superfamily. Annu. Rev. Med. 1995, 46, 443-453.
56. Rieusset, J.; Touri, F.; Michalik, L.; Escher, P.; Desvergne, B.; Niesor, E.; Wahli, W. A new selective peroxisome proliferator-activated receptor gamma antagonist with anti-obesity and antidiabetic activity. Mol. Endocrinol. 2002, 16, 2628-2644.
57. Kubota, N.; Terauchi, Y.; Miki, H.; Tamemoto, H.; Yamauchi, T.; Komeda, K.; Satoh, S.; Nakano, R.; Ishii, C.; Sugiyama, T.; Eto, K., Tsubamoto, Y.; Okuno, A.; Myrakami, K.; Sekihara, H.; Hasegawa, G.; Naito, M.; Toyoshima, Y.; Tanaka, S.; Shiota, K.; Kitamura, T.; Fujita, T.; Szaki, O.; Aizawa, S.; Kadowaki, T. PPARγ mediated high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 1999, 4, 597-609.
58. Fu, J.; Gaetani, S.; Oveisi, F.; Vo Verme, J.; Serrano, A.; Rodriquez De Fonseca, F.; Rosengarth, A.; Luecke, H.; Di Giacomo, B.; Tarzia, G.; Piomelli, D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR alpha. Nature 2003, 425, 90-93.
59. Wang, Y.X.; Lee, C.H.; Tiep, S.; Yu, R.T.; Ham, J.; Kang, H.; Evans, R.M. Peroxisome proliferator-activated receptor delta activated fat metabolism to prevent obesity. Cell 2003, 113, 159-170.
60. King, S.H.; Mayorov, A.V.; Balse-Srinivasan, P.; Hruby, V.J.; Vanderah, T.W.; Wessells, H. Melanocortin receptors, melanotropic peptides and penile erection. Curr. Top. Med. Chem. 2007, 7, 1098-1106.
61. Andersson, P.M.; Boman, A.; Seifret, E.; Skottner, A.; Torbjorn, L. Ligands to the melanocortin receptors. Expert Opin. Ther. Pat. 2001, 11, 1583-1592.
62. Speake, J.D.; Bishop, M.J. Recent advances in the development of melanocortin-4 receptor agonists. Expert Opin. Ther. Patents 2002, 12, 1631-1638.
63. Sebhat, I.; Ye, Z.; Bednarek, M.; Weinberg, D.; Nargund, R.; Fong, T.M. Melanocortin-4 receptor agonists and antagonists: Chemistry and potent therapeutic utilities. Annu. Rep. Med. Chem. 2003, 38, 31-40.
64. Bednarek, M.A.; Fong, T.M. Ligands of the melanocortin receptors, 2002-2003 update. Expert Opin. Ther. Pat. 2004, 14, 327-336.
65. Boyce, R.S.; Duhl, D.M. Melanocortin-4 receptor agonists for the treatement of obesity. Curr. Opin. Investig. Drugs 2004, 5, 1063-1071.
66. Irani, B.G.; Holder, J.R.; Todorovic, A.; Wilczynski, A.M.; Joseph, C.G.; Wilson, K.R.; Haskell-Luevano, C. Progress in the development of melanocortin receptor selective ligands. Curr. Pharm. Des. 2004, 10, 3443-3479.
67. Holder, J.R.; Haskell-Luevano, C. Melanocortin ligands: 30 years of structure-activity relationship (SAR) Studies. Med. Res. Rev. 2004, 24, 325-356.
68. Todorovic, A.; Haskell-Luevano, C. A review of melanocortin receptor small molecule ligands. Peptides 2005, 26, 2026-2036.
69. Nargund, R.P.; Strack, A.M.; Fong, T.M. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J. Med. Chem. 2006, 49, 4035-4043.
70. Yan, L.Z.; Hsiung, H.M.; Heiman, M.L.; Gadski, R.A.; Emmerson, P.J.; Hertel, J. Flora, D.; Edwards, P.; Smiley, D.; Zhang, L.; Husain, S.; Kahl, S.D.; DiMarchi, R.D.; Mayer, J. P. Structure-activity relationships of β-MSH derived melanocortin-4 receptor peptide agonists. Curr. Top. Med. Chem. 2007, 7, 1052-1067.
71. Ujjainwalla, F.; Sebhat, I.K. Small molecule ligands of the human melanocortin-4 receptor. Curr. Top. Med. Chem. 2007, 7, 1068-1084.
72. Emmerson, P.J.; Fisher, M.J.; Yan, L.Z.; Mayer, J.P. Melanocortin-4 receptor agonists for the treatment of obesity. Curr. Top. Med. Chem. 2007, 7, 1121-1130.
73. Chen, C. Recent progress toward nonpeptide ligands for the melanocortin-4 receptor. Progr. Med. Chem. 2007, 45, 111-167.
74. Nozawa, D.; Chaki, S.; Nakazato, A. Recent advances in the development of melanocortin-4 receptor ligands. Expert Opin. Ther. Pat. 2008, 18, 403-427.
75. Bakshi, R.K.; Barakat, K.J.; Nargund, R.P.; Palucki, B.L.; Patchett, A.A.; Sebhat, I.; Ye, Z.; Van Der Ploeg, L.H.T. Preparation of piperidine amino acid derivatives as melanocortin-4 receptor agonists. WO 2000/074679, 2000.
76. Palucki, B.L.; Nargund, R.P. Spiropiperidine derivatives as melanocortin receptor agonists. WO 2001/070337, 2001.
77. Palucki, B.L.; Barakat, K.J.; Guo, L.; Lai, Y.; Nargund, R.P.; Park, M.K.; Pollard, P.G.; Sebhat, I.K.; Ye, Z. Preparation of piperazinylcarbonylaminomethylcarbonylpiperidines as melanocortin-4 receptor agonists. WO 2001/070708, 2001.
78. Bakshi, R.K.; Nargund, R.P.; Ye, Z. Melanocortin receptor agonists, and preparation thereof, for therapeutic use. WO 2001/091752, 2001.
79. Bakshi, R.K.; Barakat, K.J.; Lai, Y.; Nargund, R.P.; Palucki, B.L.; Park, M.K.; Patchett, A.A.; Sebhat, I.; Ye, Z. Preparation of substituted piperidines as melanocortin receptor agonists. WO 2002/ 015909, 2002.
80. Ye, Z.; Barakat, K.J.; Guo, L.; Nargund, R.P.; Sebhat, I.K. Preparation of bridged piperidine amino acid derivatives as melanocortin receptor agonists. WO 2003/007949, 2003.
81. Bakshi, R.K.; Nargund, R.P.; Palucki, B.L.; Park, M.K.; Ye, Z. Preparation of carbamoylpiperazines as melanocortin-4 receptor agonists. WO 2004/024720, 2004.
82. Sebhat, I.K.; Martin, W.J.; Ye, Z.; Barakat, K.; Mosley, R.T.; Johnston, D.B.R.; Bakshi, R.; Palucki, B.; Weinberg, D.H.; MacNeil, T.; Kalyani, R.N.; Tang, R.; Stearns, R.A.; Miller, R.R.; Tamvakopoulos, C.; Strack, A.M.; McGowan, E.; Cashen, D.E.; Drisko, J.E.; Hom, G.J.; Howard, A.D.; MacIntyre, D.E.; van der Ploeg, L.H.T.; Patchett, A.A.; Nargund, R.P. Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3- ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4- triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonists. J. Med. Chem. 2002, 45, 4589-4593.
83. Bakshi, R.K.; Hong, Q.; Tang, R.; Kalyani, R.N.; MacNeil, T.; Weinberg, D.H.; Van der Ploeg, L.H.T.; Patchett, A.A.; Nargund, R.P. Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands. Bioorg. Med. Chem. Lett. 2006, 16, 1130-1133.
84. Sebhat, I.K.; Lai, Y.; Barakat, K.; Ye, Z.; Tang, R.; Kalyani, R.N.; Vongs, A.; MacNeil, T.; Weinberg, D.H.; Cabello, M.A.; Maroto, M.; Teran A.; Fong, T. M.; Van der Ploeg, L.H.T.; Patchett, A.A.; Nargund, R.P. Melanocortin subtype 4 receptor agonists: Structure-activity relationships about the 4-alkyl piperidine core. Bioorg. Med. Chem. Lett. 2007, 17, 5720-5723.
85. Palucki, B.L.; Park, M.K.; Nargund, R.P.; Ye, Z.; Sebhat, I.K.; Pollard, P.G.; Kalyani, R.N.; Tang, R.; MacNeil, T.; Weinberg, D.H.; Vongs, A.; Rosenblum, C.I.; Doss, G.A.; Miller, R.R.; Stearns, R.A.; Peng, Q.; Tamvakopoulos, C.; McGowan, E.; Martin, W.J.; Metzger, J.M.; Shepherd, C.A.; Strack, A.M.; MacIntyre, D.E.; Van der Ploeg, L.H.T.; Patchett, A.A. Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4- (1,1-dimethylethyl)amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- methylpiperazinecarboxamide(MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett. 2005, 15, 171-175.
86. Doss, G.A.; Miller, R.R.; Zhang, Z.; Teffera, Y.; Nargund, R.P.; Palucki, B.; Park, M.K.; Tang, Y.S.; Evans, D.C.; Baillie, T.A.; Stearns, R.A. Metabolic activation of a 1,3-disubstituted piperazine derivative: Evidence for a novel ring contraction to an imidazoline. Chem. Res. Toxicol. 2005, 18, 271-276.
87. Palucki, B.L.; Park, M.K.; Nargund, R.P.; Tang, R.; MacNeil, T.; Weinberg, D. H.; Vongs, A.; Rosenblum, C.I.; Doss, G.A.; Miller, R.R.; Stearns, R.A.; Peng, Q.; Tamvakopoulos, C.; Van der Ploeg, L.H.T.; Patchett, A.A. 2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists. Bioorg. Med. Chem. Lett. 2005, 15, 1993-1996.
88. Ye, Z.; Guo, L.; Barakat, K.J.; Pollard, P.G.; Palucki, B.L.; Sebhat, I.K.; Bakshi, R.K.; Tang, R.; Kalyani, R.N.; Vongs, A.; Chen, A.S.; Chen, H.Y.; Rosenblum, C.I.; MacNeil, T.; Weinberg, D.H.; Peng, Q.; Tamvakopoulos, C.; Miller, R.R.; Stearns, R.A.; Cashen, D.E.; Martin, W.J.; Metzger, J.M.; Strack, A.M.; MacIntyre, D.E.; Van der Ploeg, L.H.T.; Patchett, A.A.; Wyvratt, M.J.; Nargund, R.P. Discovery and activity of (1R,4S,6R)-N-[(1R)-2- [4-cyclohexyl-4-(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1- [(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2] octane-6- carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett. 2005, 15, 3501-3505.
89. Bakshi, R.K.; Hong, Q.; Olson, J.T.; Ye, Z.; Sebhat, I.K.; Weinberg, D.H.; MacNeil, T.; Kalyani, R.N.; Tang, R.; Martin, W.J.; Strack, A.; McGowan, E.; Tamvakopoulos, C.; Miller, R.R.; Stearns, R.A.; Tang, W.; Maclntyre, D.E.; van der Ploeg, L.H.T.; Patchett, A.A.; Nargund, R.P. 1-Amino-1,2,3,4-tetrahydronaphthalene- 2-carboxylic acid as a Tic mimetic: Application in the synthesis of potent human melanocortin-4 receptor selective agonists. Bioorg. Med. Chem. Lett. 2005, 15, 3430-3433.
90. Goulet, M.T.; Nargund, R.P.; Sebhat, I.K.; Ujjainwalla, F.; Walsh, T.F.; Warner, D.; Young, J.R.; Bakshi, R.K. Acylated piperidine derivatives, specifically 1-(pyrrolidinylcarbonyl)piperidines, 1- (piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses. WO 2002/068387, 2002.
91. Goulet, M.T.; Nargund, R.P.; Ujjainwalla, F.; Walsh, T.F.; Warner, D. Acylated piperidine derivatives, specifically 1-(amino-cycloalkyl) carbonyl]piperidines, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses. WO 2002/067869, 2002.
92. Ujjainwalla, F.; Chu, L.; Goulet, M.T.; Lee, B.; Warner, D.; Wyvratt, M.J. Acylated piperidine derivatives, specifically 1-(pyrrolidinylcarbonyl) piperidines, 1-(piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses. WO 2002/068388, 2002.
93. Bakshi, R.K.; Hong, Q.; Nargund, R.P.; Pollard, P.G.; Sebhat, I.K.; Ujjainwalla, F.; Ye, Z. Preparation of acylated piperazine derivatives as melanocortin-4 receptor agonists for the treatment of obesity, diabetes mellitus and sexual dysfunction, and pharmaceutical compositions thereof. WO 2004/078716, 2004.
94. Guo, L.; He, S.; Jian, T.; Lai, Y.; Liu, J.; Nargund, R.P.; Sebhat, I.K.; Ujjainwalla, F.; Ye, Z.; Young, J.R. Preparation of cyclo-alkylcarbonyl or heterocycloalkylcarbonyl-substituted spiropiperidines as melanocortin-4 receptor agonists for the treatment of conditions such as obesity. WO 2004/089307, 2004.
95. Sings, H.; Ujjainwalla, F. Preparation of 4-aryl-1-(pyrrolidinyl-carbonyl)piperidines as melanocortin-4 receptor agonists. WO 2005/009950, 2005.
96. Barakat, K.J.; Guo, L.; Liu, J.; Nargund, R.P.; Sebhat, I.K.; Ye, Z. Preparation of piperidine derivatives as melanocortin-4 receptor agonists. WO 2006/019787, 2006.
97. Bakshi, R.K.; Dellureficio, J.P.; Nargund, R.P. Preparation of piperidine derivatives as melanocortin-4 receptor agonists. WO 2006/ 020277, 2006.
98. Jian, T.; Liu, J.; Nargund, R.P. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2007/041052, 2007.
99. Bakshi, R.K.; Hong, Q.; Nargund, R.P. Preparation of acylated piperidines and related compounds as melanocortin-4 receptor agonists. WO 2007/041061, 2007.
100. Bakshi, R.K.; Dellureficio, J.P.; Dobbelaar, P.H.; Guo, L.; He, S.; Hong, Q.; Nargund, R.P.; Ye, Z. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of obesity, nicotine addiction, alcoholism and sexual dysfunction. WO 2007/047496, 2007.
101. Bakshi, R.K.; Dellureficio, J.P.; Hong, Q.; Jian, T.; Liu, J.; Nargund, R.P.; Ye, Z. Preparation of piperidine derivatives as melanocortin-4 receptor modulators. WO 2008/039418, 2008.
102. Guo, L.; Ye, Z.; Ujjainwalla, F.; Sings, H.L.; Sebhat, I.K.; Huber, J.; Weinberg, D.H.; Tang, R.; MacNeil, T.; Tamvakopoulos, C.; Peng, Q.; MacIntyre, E.; van der Ploeg, L.H.T.; Goulet, M.T.; Wyvratt, M.J.; Nargund, R.P. Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators. Bioorg. Med. Chem. Lett. 2008, 18, 3242-3247.
103. Ujjainwalla, F.; Warner, D.; Walsh, T.F.; Wyvratt, M.J.; Zhou, C.; Yang, L.; Kalyani, R.N.; MacNeil, T.; Van der Ploeg, L.H.T.; Rosenblum, C.I.; Tang, R.; Vongs, A.; Weinberg, D.H.; Goulet, M.T. Design and syntheses of melanocortin subtype-4 receptor agonists: Evolution of the pyridazinone archetype. Bioorg. Med. Chem. Lett. 2003, 13, 4431-4435.
104. Ujjainwalla, F.; Warner, D.; Snedden, C.; Grisson, R.D.; Walsh, T.F.; Wyvratt, M.J.; Kalyani, R.N.; MacNeil, T.; Tang, R.; Weinberg, D.H.; Van der Ploeg, L.H.T.; Goulet, M.T. Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: Discovery of the dihydropyridazinone motif. Bioorg. Med. Chem. Lett. 2005, 15, 4023-4028.
105. Dyck, B.P.; Goodfellow, V.; Phillips, T.; Parker, J.; Zhang, X.; Chen, C.; Tran, J.A.; Pontillo, J.; Tucci, F.C. Preparation of peptides as ligands of melanocortin receptors. WO 2003/031410, 2003.
106. Pontillo, J.; Marinkovic, D.; Lanier, M.C.; Tran J.A.; Arellano, M.; Parker, J.; Nelson, J.; Chen, C.; Chen, C.; Jiang, W.; White, N.; Tucci, F.C. Substituted piperazine derivatives as melanocortin receptor ligands, and their preparation, pharmaceutical compositions, and use. WO 2003/094918, 2003.
107. Chen, C.; Tran, J.A.; Tucci, F.C.; Chen, W.-C. C.; Jiang, W.; Marinkovic, D.; Arellano, M.; White, N. Preparation of piperazinyl carboxamide and related cyclic homologs as ligands of melanocortin receptors and compositions and methods related thereto. WO 2005/040109, 2005.
108. Dyck, B.; Parker, J.; Phillips, T.; Carter, L.; Murphy, B.; Summers, R.; Hermann, J.; Baker, T.; Cismowski, M.; Saunders, J.; Goodfellow, V. Aryl piperazine melanocortin MC4 receptor agonists. Bioorg. Med. Chem. Lett. 2003, 13, 3793-3796.
109. Pontillo, J.; Tran, J A.; Arellano, M.; Fleck, B.A.; Huntley, R.; Marinkovic, D.; Lanier, M.; Nelson, J.; Parker, J.; Saunders, J.; Tucci, F.C.; Jiang, W.; Chen, C. W.; White, N.S.; Foster, A.C.; Chen, C. Structure-activity relationships of piperazinebenzylamines as potent and selective agonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. 2004, 14, 4417-4423.
110. Tran, J.A.; Pontillo, J.; Arellano, M.; White, N.S.; Fleck, B.A.; Marinkovic, D.; Tucci, F.C.; Lanier, M.; Nelson, J.; Saunders, J.; Foster, A.C.; Chen, C. Identification of agonists and antagonists of the human melanocortin-4 receptor from piperazinebenzylamines. Bioorg. Med. Chem. Lett. 2005, 15, 833-837.
111. Pontillo, J.; Tran, J. A.; White, N.S.; Arellano, M.; Fleck, B A.; Marinkovic, D.; Tucci, F.C.; Saunders, J.; Foster, A.C.; Chen, C. Structure-activity relationship studies on a series of cyclohexylpiperazines bearing a phenylacetamide as ligands of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. 2005, 15, 5237-5240.
112. Tran, J.A.; Chen, C.W.; Jiang, W.; Tucci, F.C.; Fleck, B.A.; Marinkovic, D.; Arellano, M.; Chen, C. Pyrrolidines as potent functional agonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. 2007, 17, 5165-5170.
113. Jiang, W.; Tran, J. A.; Tucci, F.C.; Fleck, B.A.; Hoare, S.R.; Markison, S.; Wen, J.; Chen, C.W.; Marinkovic, D.; Arellano, M.; Foster, A.C.; Chen, C. Synthesis and characterization of pyrrolidine derivatives as potent agonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. 2007, 17, 6546-6552.
114. Chen, C.; Jiang, W.; Tran, J.A.; Tucci, F.C.; Fleck, B.A.; Markison, S.; Wen, J.; Madan, A.; Hoare, S.R.; Foster, A.C.; Marinkovic, D.; Chen, C.W.; Arellano, M.; Saunders, J. Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. 2008, 18, 129-136.
115. Backer, R.T.; Briner, K.; Collado Cano, I.; De Frutos-Garica, O.; Doecke, C. W.; Fisher, M J.; Garcia-Paredes, C.; Kuklish, S.L.; Mancoso, V.; Martinelli, M.J.; Mateo Herranz, A.I.; Mullaney, J.T.; Ornstein, P.L.; Wu, Z.; Xie, C. Preparation of piperazinyl and hexahydro-1,4-diazepinyl amino acid derivatives as melanocortin receptor agonists. WO 2002/059095, 2002.
116. Backer, R.T.; Briner, K.; Doecke, C.W.; Fisher, M. J.; Kuklish, S.L.; Mancuso, V.; Martinelli, M.J.; Mullaney, J.T.; Xie, C. Preparation of piperidinyl and piperazinyl amino acid derivatives as melanocortin receptor agonists. WO 2002/059107, 2002.
117. Biggers, C.K.; Briner, K.; Doecke, C.W.; Fisher, M.J.; Hertel, L.W.; Mancoso, V.; Martinelli, M.J.; Mayer, J.P.; Ornstein, P.L.; Richardson, T.I.; Shah, J.A.; Shi, Q.; Wu, Z.; Xie, C. Preparation of piperazinyl and hexahydro-1,4-diazepinyl amino acid derivatives as melanocortin receptor agonists. WO 2002/059108, 2002.
118. Briner, K.; Doecke, C.W.; Mancoso, V.; Martinelli, M.J.; Richardson, T.I.; Rothhaar, R.R.; Shi, Q.; Xie, C. Preparation of piperazine- and piperidine-derivatives as melanocortin receptor agonists. WO 2002/ 059117, 2002.
119. Backer, R.T.; Collado, C.I.; De Frutos-Garcia, O.; Doecke, C.W.; Fisher, M.J.; Kuklish, S.L.; Mancuso, V.; Martinelli, M.J.; Mullaney, J.T.; Ornstein, P. L.; Xie, C. Preparation of piperazinyl amino acid derivatives as melanocortin receptor agonists. WO 2003/061660, 2003.
120. Richardson, T.I.; Ornstein, P.L.; Briner, K.; Fisher, M.J.; Backer, R.T.; Biggers, C.K.; Clay, M.P.; Emmerson, P.J.; Hertel, L.W.; Hsiung, H.M.; Husain, S.; Kahl, S.D.; Lee, J.A.; Lindstrom, T.D.; Martinelli, M.J.; Mayer, J.P.; Mullaney, J.T.; O'Brien, T.P.; Pawlak, J.M.; Revell, K.D.; Shah, J.; Zgombick, J.M.; Herr, R.J.; Melekhov, A.; Sampson, P.B.; King, C.-H.R. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor. J. Med. Chem. 2004, 47, 744-755.
121. Fisher, M.J.; Backer, R.T.; Husain, S.; Hsiung, H.M.; Mullaney, J.T.; O'Brian, T. P.; Ornstein, P.L.; Rothhaar, R.R.; Zgombick, J.M.; Briner, K. Privileged structure-based ligands for melanocortin receptors-tetrahydroquinolines, indoles, and aminotetralines. Bioorg. Med. Chem. Lett. 2005, 15, 4459-4462.
122. Fisher, M.J.; Backer, R.T.; Collado, I.; De Frutos, O.; Husain, S.; Hsiung, H.M.; Kuklish, S.L.; Mateo, A.I.; Mullaney, J.T.; Ornstein, P.L.; Paredes, C.G.; O'Brian, T.P.; Richardson, T.I.; Shah, J.; Zgombick, J.M.; Briner, K. Privileged structure based ligands for melanocortin receptors-Substituted benzylic piperazine derivatives. Bioorg. Med. Chem. Lett. 2005, 15, 4973-4978.
123. Kuklish, S.L.; Backer, R.T.; Briner, K.; Doecke, C.W.; Husain, S.; Mullaney, J.T.; Ornstein, P.L.; Zgombick, J.M.; O'Brien, T.P.; Fisher, M.J. Privileged structure based ligands for melanocortin receptors-4,4-disubstituted piperidine derivatives. Bioorg. Med. Chem. Lett. 2006, 16, 3843-3846.
124. Fotsch, C.H.; Croghan, M.; Doherty, E.M.; Kelly, M.G.; Norman, M.H.; Smith, D.M.; Tamayo, N.; Xi, N.; Xu, S. Substituted piperidines as modulators of the melanocortin receptor. WO 2003/009847, 2003.
125. Fotsch, C.H.; Arasasingham, P.; Bo, Y.; Chen, N.; Goldberg, M.H.; Han, N.; Hsieh, F.-Y.; Kelly, M.G.; Liu, Q.; Norman, M.H.; Smith, D.M.; Stec, M.; Tamayo, N.; Xi, N.; Xu, S. Preparation of substituted piperazines as agonists of melanocortin receptors useful against obesity and diabetes. WO 2003/009850, 2003.
126. 2. Bioorg. Med. Chem. Lett. 2003, 13, 2337-2340.
127. Xi, N.; Hale, C.; Kelly, M.G.; Norman, M.H.; Stec, M.; Xu, S.; Baumgartner, J.W.; Fotsch, C. Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core. Bioorg. Med. Chem. Lett. 2004, 14, 377-381.
128. Fotsch, C.; Han, N.; Arasasingham, P.; Bo, Y.; Carmouche, M.; Chen, N.; Davis, J.; Goldberg, M.H.; Hale, C.; Hsieh, F.-Y.; Kelly, M G.; Liu, Q.; Norman, M.H.; Smith, D.M.; Stec, M.; Tamayo, N.; Xi, N.; Xu, S.; Bannon, A.W.; Baumgartner, J.W. Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides. Bioorg. Med. Chem. Lett. 2005, 15, 1623-1627.
129. Carpino, P.A.; Cole, B.M.; Morgan, B.P. Preparation of heterocycle compounds as melanocortin receptor ligands. WO 2002/000654, 2002.
130. Yu, G.; Macor, J.; Herpin, T.; Lawrence, R.M.; Morton, G.C.; Ruel, R.; Poindexter, G.S.; Ruediger, E.H.; Thibault, C. Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors. WO 2002/ 070511, 2002.
131. Yu, G.; Macor, J.; Herpin, T.; Lawrence, R.M.; Morton, G.C.; Ruel, R.; Poindexter, G.S.; Ruediger, E.H.; Thibault, C. Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors. WO 2002/ 079146, 2002.
132. Soeberdt, M.; Weyermann, P.; Von Sprecher, A. Substituted N-benzyllactam derivatives as melanocortin-4 receptor agonists, and their therapeutic use. EP 1538159, 2005.
133. Calabrese, A.A.; Fradet, D.S.; Hepworth, D.; Lansdell, M. Preparation of Pyrrolidinyl(carbonyl) piperidines as melanocortin receptor 4 agonists for therapeutic use. US 2005/176772, 2005.
134. Kondo, H.; Kanzawa, K.; Hirabayashi, R.; Shimada, I.; Nakanishi, K.; Kurama, T.; Takeuchi, H.; Lee, K. Spiropiperidines useful for antiobesity agents. JP 2005/041839, 2005.
135. Braun, A.; Courtemanche, G.; Crespin, O.; Fett, E.; Pascal, C. Preparation of oxopiperidines, particularly piperidino-D-phenylalanine derivatives, as melanocortin receptor agonists. FR 2873690, 2006.
136. Braun, A.; Cornet, B.; Courtemanche, G.; Crespin, O.; Fett, E.; Pascal, C. Preparation of aminopiperidines, particularly aminopiperidino-D-phenylalanine derivatives, as melanocortin receptor agonists. FR 2873691, 2006.
137. Braun, A.; Cornet, B.; Courtemanche, G.; Crespin, O.; Pascal, C. Preparation of aminotropane derivatives and their therapeutic applications. FR 2873693, 2006.
138. Komatsu, Y.; Shima, K.; Naka, T.; Akahoshi, F. Preparation of piperidines as melanocortin 4 receptor agonists and their pharmaceutical compositions for treatment of obesity, excessive appetite, sexual dysfunction, and infertility. JP 2006/282602, 2006.
139. Andrews, M.D.; Brown, A.D.; Fradet, D.S.; Lansdell, M.I. Preparation of piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds as MCR4 agonists. WO 2007/015162, 2007.
140. Soeberdt, M.; Weyermann, P.; Deppe, H.; Von Sprecher, A.; Feurer, A.; Lescop, C.; Henneboehle, M. Preparation of 1-(2-amino-3-phenylpropanoyl)-4-phenylpiperidine derivatives as melanocortin-4 receptor modulators. WO 2007/096186, 2007.
141. Andrews, M.D.; Brown, A.D.; Lansdell, M.I.; Summerhill, N.W. Preparation of piperidinoylazinylpyrrolidines as melanocortin type 4 receptor agonists. WO 2007/096763, 2007.
142. Komatsu, Y.; Shima, K.; Naka, T.; Akaboshi, F. Preparation of novel aminopyrrolidines, their use as melanocortin 4 receptor (MC4R) agonists, and pharmaceutical compositions for treatment of obesity, diabetes, and infertility. JP 2007/131570, 2007.
143. Choi, S.P.; Ahn, I.A.; Lee, S.H.; Lee, S.D.; Shin, M.S.; Lee, K.; Choi, D.Y.; Shim, D.S.; Yim, H.J.; Yoon, M.K.; Chung, S.Y.; Lee, J.A.; Ha, Y.H.; Kim, Y.K.; Park, O.; Lee, H.M.; Kim, Y.H. Preparation of amino acid aminopyrrolidinyl amides as melanocortin receptor agonists. WO 2008/ 007930, 2008.
144. Ruel, R.; Herpin, T.F.; Iben, L.; Luo, G.; Martel, A.; Mason, H.; Mattson, G.; Poirier, B.; Ruediger, E.H.; Shi, D.; Thibault, C.; Yu, G.; Antal, Z. I.; Poindexter, G.S.; Macor, J.E. β-Alanine dipeptides as MC4R agonists. Bioorg. Med. Chem. Lett. 2003, 13, 4341-4344.
145. Chu, D.; Boyce, R.S.; Duhl, D.; Chang, B. Preparation of novel guanidino compounds as melanocortin-4 receptor agonists. WO 2002/081443, 2002.
146. Mazur, A.W.; Tian, X.; Hu, X.E.; Ebetino, F.H. Preparation of pyrrolidine, piperidine, or piperazine amino acid derivatives as melanocortin receptor ligands. WO 2002/085925, 2002.
147. Eisinger, M.; Fitzpatrick, L.J.; Lee, D.H.; Pan, K.; Plata-Salaman, C.; Reitz, A. B.; Smith-Swintosky, V.L.; Zhao, B. Preparation of 1,2,4-thiadiazole derivatives as melanocortin receptor modulators. WO 2003/040117, 2003.
148. Eisinger, M.; Fitzpatrick, L.J.; Lee, D.H.; Pan, K.; Plata-Salaman, C.; Reitz, A.B.; Smith-Swintosky, V.L.; Zhao, B. Preparation of 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators. WO 2003/040118, 2003.
149. Boyce, R.; Chu, D. Preparation of aryl- or heteroaryl-containing guanidines as melanocortin-4-receptor agonists useful against disorders such as obesity or type II diabetes. WO 2003/066597, 2003.
150. Boyce, R.S.; Aurrecoechea, N.; Chu, D.; Smith, A. Preparation of (guanidino)quinazolinones as MC-4R agonists for treatment of obesity and type II diabetes. WO 2003/099818, 2003.
151. Ebetino, F.H.; Tian, X.; Mazur, W.A.; Colson, A.-O. Preparation of piperazine amino acid derivatives and related compounds as melanocortin receptor ligands. WO 2004/037797, 2004.
152. Conde-Frieboes, K.W.; Ankersen, M.; Sensfuss, U.; Wulff, B.S.; Thogersen, H.; Lustenberger, P.; Rudolf, K.; Krist, B.; Mueller, S.; Stenkamp, D.; Schindler, M.; Wieland, H.; Arndt, K. Preparation of piperazinedione derivatives for use in treating obesity. WO 2004/048345, 2004.
153. Sharma, S.D.; Shi, Y.-Q.; Rajpurohit, R.; Wu, Z.; Purma, P.; Shadiack, A.M.; Burris, K.D. Preparation of piperazine melanocortin receptor-specific compounds. US 2004/224957, 2004.
154. Boyce, R.S.; Aurrecoechea, N.; Chu, D.; Smith, A.; Conlee, C.R.; Thompson, B.D.; De Armas, K.J.; Musso, D.L.; Barvian, K.K.; Thomson, S.A.; Swain, W.R.; Du, K.S.; Chauder, B.A.; Speake, J.D.; Bishop, M.J. Preparation of guanidino-substituted quinazolinone compounds as MC-4R agonists. WO 2004/112793, 2004.
155. Boyce, R.S.; Speake, J.D.; Phillips, J. Preparation of piperazinylguanidinoquinazolinones as melanocortin-4 receptor (MC-4R) agonists with reduced bioaccumulation. WO 2005/051391, 2005.
156. Mjalli, A.M.M.; Gaddam, B.R.; Qabaja, G.; Subramanian, G.; Zhu, J.; Dankwardt, J.; Arimilli, M.N.; Andrews, R.C.; Victory, S.; Tian, Y.E. Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators. WO 2005/103022, 2005.
157. Szewczyk, J.R.; Speake, J.D.; Sammond, D.M.; Sherrill, R.G. Preparation of diazepinediones as ligands of melanocortin 1 and/or 4 receptors. WO 2005/118573, 2005.
158. Szewczyk, J.R.; Donaldson, K.H. Preparation of benzodiazepines for use in treating illnesses related to the melanocortin 4 receptor. US 2006/ 003991, 2006.
159. Sharma, S.D.; Shi, Y.-Q.; Burris, K.; Purma, P.; Bonuga, Y.R. Preparation of diamine-containing, tetra-substituted piperazine amino acid derivatives as melanocortin receptor modulators. WO 2008/017852, 2008.
160. Tian, X.; Mishra, R.K.; Switzer, A.G.; Hu, X.E.; Kim, N.; Mazur, A.W.; Ebetino, F.H.; Wos, J.A.; Crossdoersen, D.; Pinney, B.B.; Farmer, J.A.; Sheldon, R.J. Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg. Med. Chem. Lett. 2006, 16, 4668-4673.
161. Tian, X.; Switzer, A.G.; Derose, S.A.; Mishra, R.K.; Solinsky, M.G.; Mumin, R.N.; Ebetino, F.H.; Jayasinghe, L.R.; Webster, M.E.; Colson, A.-O.; Crossdoersen, D.; Pinney, B.B.; Farmer, J.A.; Dowty, M.E.; Obringer, C.M.; Cruze, C.A.; Burklow, M.L.; Suchanek, P.M.; Dong, L.; Dirr, M.K.; Sheldon, R.J.; Wos, J.A. Discovery of orally bioavailable 1,3,4-trisubstituted 2- oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents. J. Med. Chem. 2008, 51, 6055-6066.
162. Pan, K.; Scott, M. K.; Lee, D.H.S.; Fitzpatrick, L.J.; Crooke, J.J.; Rivero, R.A.; Rosenthal, D.I.; Vaidya, A.H.; Zhao, B.; Reitz, A.B. 2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. Bioorg. Med. Chem. 2003, 11, 185-192.
163. Ludwig, D.S.; Tritos, N.A.; Mastaitis, J.W.; Kulkarni, R.; Kokkotou, E.; Elmquist, J.; Lowell, B.; Flier, J.S.; Maratos-Flier, E. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J. Clin. Invest. 2001, 107, 379-386.
164. Marsh, D.J.; Weingarth, D.T.; Novi, D.E.; Chen, H.Y.; Trumbauer, M.E.; Chen, A.S.; Guan, X.M.; Jiang, M.M.; Feng, Y.; Camacho, R.E.; Shen, Z.; Frazier, E.G.; Yu, H.; Metzger, J.M.; Kuca, S.J.; Shearman, L.P.; Gopal-Truter, S.; MacNeil, D.J.; Strack, A.M.; MacIntyre, D.E.; Vander Ploeg, L.H.; Qian, S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. USA 2002, 99, 3240-3245
165. Mendez-Andino, J.L.; Wos, J.A. MCH-R1 antagonists: What is keeping most research programs away from the clinic? Drug Discov. Today 2007, 12, 972-979.
166. Carpenter, A.J.; Hertzog, D.L. Melanin-concentrating hormone receptor antagonists as potential antiobesity agents. Expert Opin. Ther. Pat. 2002, 12, 1639-1646.
167. Collins, C.A.; Kym, P.R. Prospects for obesity treatment: MCH receptor antagonists. Curr. Opin. Investig. Drugs 2003, 4, 386-394.
168. Kowalski, T.J.; Mcbriar, M.D. Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin. Investig. Drugs 2004, 13, 1113-1122.
169. MeBriar, M.D.; Kowalski, T.J. Melanin-concentrating hormone as a therapeutic target. Ann. Rep. Med. Chem. 2005, 40, 119-133.
170. Kowalski, T.F; Sasikumar, T. Melanin-concentrating hormone receptor-1 antagonists as antiobesity therapeutics. Biodrugs 2007, 21, 311-321.
171. Handlon, A.L.; Zhou. H. Melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. J. Med. Chem 2006, 49, 4017-4022.
172. Luthin, D.R. Anti-obesity effects of small molecule melanin-concentrating hormone receptor1 (MCHR1) antagonists. Life Sciences 2007, 81, 423-440.
173. Bednarek, M.A. Peptide ligands for the melanin-concentrating hormone (MCH) receptor 1. Curr. Top. Med. Chem. 2007, 7, 1425-1432.
174. DeVita, R.J. Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists. Curr. Top. Med. Chem. 2007, 7, 1433-1439.
175. McBriar, M.D. Melanin concentrating hormone receptor antagonists as antiobesity agents: From M2 to MCHR-1. Curr. Top. Med. Chem. 2007, 7, 1440-1454.
176. Hertzog, D.L.; Witty, D.R. Biphenyl amides and isosteres as MCH R1 antagonists. Curr. Top. Med. Chem. 2007, 7, 1455-1470.
177. Kym, P.R.; Judd, A.S.; Lynch, J.K.; Lyengar, R.; Vasudevan, A.; Souers, A.J. Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists. curr. Top. Med. Chem. 2007, 7, 1471-1488.
178. Rokosz, L.L. Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Expert Opin. Drug Discov. 2007, 2, 1301-1327.
179. Rivera, G.; Bocanegra-Garcia, V.; Galiano, S.; Cirauqui, N.; Ceras, J.; Pérez, S.; Aldana, I.; Monge, A. Melanin-concentrating hormone receptor 1 antagonists: A new perspective for the pharmacologic treatment of obesity. Curr. Med. Chem. 2008, 15, 1025-1043.
180. Judd, A.S.; Souers, A.J.; Kym, P.R. Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity. Curr. Top. Med. Chem. 2008, 8, 1152-1157.
181. Bakthavatchalam, R.; Hutchison, A.; Thurkauf, A. Preparation of 1-phenyl-2-piperazinomethylcyclopropanes as melanin concentrating hormone receptor ligands. WO 2002/004433, 2002.
182. Hutchison, A.; Peterson, J.; Doller, D.; Gustavson, L.E.; Caldwell, T.; Yoon, T.Y.; Pringle, W.; Bakthavatchalam, R.; Shen, Y.; Steenstra, C.; Yin, H.; De, S.R.; He, X.-S. Substituted 1-benzyl-4-arylpiperazine analogs as melanin concentrating hormone receptor ligands. WO 2002/ 094799, 2002.
183. De Simone, R.; Peterson, J.; Steenstra, C.; Shen, Y.; Gustavson, L.; Bakthavatchalam, R.; Hutchison, A. Melanin concentrating hormone receptor ligands: Substituted benzimidazole analogs and their uses and pharmaceutical preparations. WO 2003/059289, 2003.
184. Hutxhinson, A.J.; Chenard, B.L.; Tarrant, J.G.; Li, G.; Ghosh, M.; Luke, G.P.; Peterson, J.M.; Pringle, W.C.; O'Donnell, M.-M. E.; Lee, K.; Gustavson, L.M.; Doller, D. Preparation of substituted 1- benzyl-4-substituted piperazines as MCH receptor modulators. WO 2005/ 110982, 2005.
185. Hutchison, A.J.; Chenard, B.L.; Luke, G.P. Substituted 1- heteroaryl-4-substituted piperazine and piperidine analog MCH receptor modulators, and uses thereof. WO 2005/110989, 2005.
186. Doller, D.; Hutchison, A.J.; Chenard, B.L.; Desimone, R.W. Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor and their preparation, pharmaceutical compositions, and use for treatment of obesity, diabetes, eating and sexual disorders. WO 2006/ 015279, 2006.
187. Chenard, B.L.; Ghosh, M.; Doller, D.; Hutchison, A.J.; Li, G. Aryl-substituted 8-azabicyclo[3.2.1]octane compounds as melanin-concentrating hormone receptor ligands, their preparation, pharmaceutical compositions, and use in therapy. WO 2006/04417, 2006.
188. Ghosh, M.; Seekamp, C.K.; Zhang, X.; Tarrant, J.G.; Lee, C.-W.; Kaiser, B.; Zablocki, M.-M.; Chenard, B.L.; Doller, D.; Yamaguchi, Y.; Wustrow, D.J.; Li, G. Aminopiperidines and related compounds as MCH modulators and their preparation, pharmaceutical compositions and use in the treatment of metabolic, feeding and sexual disorders. WO 2008/016811, 2008.
189. DailyDrugNews.com (Daily Essentials) May 7, 2007: NGD-4715 for obesity completes first-in-man study. Available from: http://www.dailydrugnews.com/home_daily/index.cfm
190. DailyDrugNews.com (Daily Essentials) January 10, 2008: Neurogen reports results of follow-up component of phase I study of NGD-4715 for obesity. Available from: http://www.dailydrugnews.com/home_daily/ index.cfm
191. Johnson, C.N.; Jones, M.; O'Toole, C.A.; Stemp, G.; Thewlis, K.M.; Witty, D. Preparation of carboxamide compounds and their use as antagonists of a human 11CBY receptor. WO2002/010146, 2002.
192. Carpenter, A.J.; Cooper, J.P.; Handlon, A.L.; Hertzog, D.L.; Hyman, C.E.; Guo, Y.C.; Speake, J.D.; Witty, D.R. Preparation of pyrimidinones as melanin concentrating hormone receptor 1 antagonists. WO 2003/033476, 2003.
193. Armstrong, S.A.; Hamprecht, D.W.; Jones, M.; Witty, D.R.; Al-Barazanji, K.A.; Tadayyon, M. Preparation of lactam derivatives as antagonists for human 11CBY receptors. WO 2003/033480, 2003.
194. Barvian, K.K.; Carpenter, A.J.; Cooper, J.P.; Feldman, P.L.; Guo, Y.C.; Handlon, A.L.; Hertzog, D.L.; Hyman, C.E.; Peat, A.J.; Peckham, G.E.; Speake, J.D.; Swain, W.R.; Tavares, F.X.; Zhou, H. Preparation of pyrimidinones as melanin concentrating hormone receptor 1 antagonists. WO 2004/092181, 2004.
195. Barvian, K.K.; Handlon, A.L.; Hertzog, D.L.; Hyman, C.E. Preparation of 3-(4-aminophenyl)thienopyrimid-4-ones as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety. WO 2005/042541, 2005.
196. Witty, D.R.; Bateson, J.H.; Hervieu, G.J.; Jeffrey, P.; Johnson, C.N.; Muir, A.I.; O'Hanlon, P.J.; Stemp, G.; Stevens, A.J.; Thewlis, K.M.; Wilson, S.; Winborn, K.Y. SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): Discovery of antagonist SB-568849. Bioorg. Med. Chem. Lett. 2006, 16, 4865-4871.
197. Witty, D.R.; Bateson, J.; Hervieu, G.J.; Al-Barazanji, K.; Jeffrey, P.; Hamprecht, D.; Haynes, A.; Johnson, C.N.; Muir, A.I.; O'Hanlon, P.J.; Stemp, G.; Stevens, A.J.; Thewlis, K.; Winborn, K.Y. Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849. Bioorg. Med. Chem. Lett. 2006, 16, 4872-4878.
198. Hertzog, D.L.; Al-Barazanji, K.A.; Bigham, E.C.; Bishop, M.J.; Britt, C.S.; Carlton, D.L.; Cooper, J.P.; Daniels, A.J.; Garrido, D.M.; Goetz, A.S.; Grizzle, M.K.; Guo, Y.C.; Handlon, A.L.; Ignar, D.M.; Morgan, R.O.; Peat, A.J.; Tavares, F.X.; Zhou, H. The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 4723-4727.
199. Carpenter, A.J.; Al-Barazanji, K.A.; Barvian, K.K.; Bishop, M.M.; Britt, C.S.; Cooper, J.P.; Goetz, A.S.; Grizzle, M.K.; Hertzog, D.L.; Ignar, D.M.; Morgan, R.O.; Peckham, G.E.; Speake, J.D.; Swain, W.R. Novel benzimidazole-based MCH R1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 4994-5000.
200. Tavares, F.X.; Al-Barazanji, K.A.; Bigham, E.C.; Bishop, M.J.; Britt, C.S.; Carlton, D.L.; Feldman, P.L.; Goetz, A.S.; Grizzle, M.K.; Guo, Y.C.; Handlon, A.L.; Hertzog, D.L.; Ignar, D.M.; Lang, D.G.; Ott, R.J.; Peat, A.J.; Zhou, H.-Q. Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1. J. Med. Chem. 2006, 49, 7095-7107.
201. Tavares, F.X.; Al-Barazanji, K.A.; Bishop, M.J.; Britt, C.S.; Carlton, D.L.; Cooper, J.P.; Feldman, P.L.; Garrido, D.M.; Goetz, A.S.; Grizzle, M.K.; Hertzog, D.L.; Ignar, D.M.; Lang, D.G.; McIntyre, M.S.; Ott, R.J.; Peat, A.J.; Zhou, H.-Q. 6-(4- Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist. J. Med. Chem. 2006, 49, 7108-7118.
202. Kato, K.; Terauchi, J.; Mori, M.; Suzuki, N.; Shimomura, Y.; Takekawa, S.; Ishihara, Y. Preparation of N-tetrahydronaphthalenyl carboxamides as melanin concentrating hormone antagonists. WO 2001/ 021577, 2001.
203. Ishihara, Y.; Suzuki, N.; Takekawa, S. Preparation of 2- (aminomethyl or heterocyclylmethyl)-6-aminoquinoline and - naphthalene derivatives as melanin concentrating hormone antagonists. WO 2001/082925, 2001.
204. Ishihara, Y.; Terauchi, J.; Suzuki, N.; Takekawa, S.; Aso, K. Preparation of benzoaromatic derivatives as melanin concentrating hormone antagonists. WO 2001/087834, 2001.
205. Ishihara, Y.; Kamata, M.; Takekawa, S.; Suzuki, N.; Kato, K. Preparation of quinoline derivatives as melanin-concentrating hormone antagonists. WO 2003/035624, 2003.
206. Ishihara, Y.; Kamata, M.; Takekawa, S. Preparation of N-phenethylpiperidine- 1-carboxamide, N-phenethylbenzamides, and N-phenethylbiphenyl-4-carboxamide derivatives as melanin-concentrating hormone antagonists. WO 2004/072018, 2004.
207. Moriya, M.; Kanatani, A.; Iwaasa, H.; Ishihara, A.; Fukami, T. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient. WO 2004/011440, 2004.
208. Moriya, M.; Suzuki, T.; Ishihara, A.; Iwaasa, H.; Kanatani, A. Preparation of pyrimidine derivatives having 2-aminoquinoline moiety as MCH receptor antagonists. WO 2004/103992, 2004.
209. Kishino, H.; Moriya, M.; Sakamoto, T.; Takahashi, H.; Sakuraba, S.; Suzuki, T.; Kanatani, A. Preparation of imidazopyridine derivatives as melanin-concentrating. hormone receptor antagonists. WO 2005/016928, 2005.
210. Ishihara, Y.; Kamata, M.; Takekawa, S.; Suzuki, N.; Kato, K. Preparation of quinoline derivatives as melanin-concentrating hormone antagonists. WO 2003/035624, 2003.
211. Hu, X.E.; Wos, J.A.; Dowty, M.E.; Suchanek, P.M.; Ji, W.; Chambers, J.B.; Benoit, S.C.; Clegg, D.J.; Reizes, O. Small-molecule melanin-concentrating hormone-1 receptor antagonists require brain penetration for inhibition of food intake and reduction in body weight. J. Pharmacol. Exp. Ther. 2008, 324, 206-213.
212. Warshakoon, N.C.; Sheville, J.; Bhatt, R.T.; Ji, W.; Mendez-Andino, J.L.; Meyers, K.M.; Kim, N.; Wos, J.A.; Mitchell, C.; Paris, J.L.; Pinney, B.B.; Reizes, O.; Hu, X.E. Design and synthesis of substituted quinolines as novel and selective melanin concentrating hormone antagonists as anti-obesity agents. Bioorg. Med. Chem. Lett. 2006, 16, 5207-5211.
213. Hu, X.E. Preparation of substituted naphthalene amides as melanin concentrating hormone antagonists for disease treatment. WO 2008/001160, 2008.
214. Goodfellow, V.; Rowbottom, M.; Dyck, B.P.; Tamiya, J.; Zhang, M.; Grey, J.; Vickers, T.; Kiankarimi, M.; Wade, W.; Hudson, S.C. Preparation of bis(3-aminopyrrolidin-1-yl)methanones as melanin-concentrating hormone receptor antagonists for treatment of obesity and other disorders. WO 2004/080411, 2004.
215. Goodfellow, V.; Rowbottom, M.; Dyck, B.P.; Tamiya, J.; Zhang, M.; Grey, J.; Vickers, T.D. Preparation of carboxamidopyrrolidines as melanin-concentrating hormone receptor antagonists and compositions and methods related thereto. WO 2004/081005, 2004.
216. Huang, C.Q.; Baker, T.; Schwarz, D.; Fan, J.; Heise, C.E.; Zhang, M.; Goodfellow, V.S.; Markison, S.; Gogas, K.R.; Chen, T.; Wang, X.-C.; Zhu, Y.-F. 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 3701-3706.
217. Beck, J.P.; Wakefield, B.D.; Cordier, F.L.; Dominguez-Manzanares, E.; Gardinier, K.M.; Greenen, P.M.; Savin, K.A. Preparation of N-benzothiazolyl(or benzoxazolyl) amides as novel MCH receptor antagonists for treating and preventing symptoms associated with obesity and related diseases. WO 2006/066173, 2006.
218. Masui, M.; Yukioka, H.; Iwakawa, T.; Hasegawa, Y. Benzene amide derivatives as melanin-concentrating hormone receptor antagonists, pharmaceutical compositions containing them. JP 2006/176443, 2006.
219. Urbanek, R.; Brown, D.; Steelman, G.; Blackwell, W.; Wesolowski, S.; Wang, X. Preparation of azabicyclooctyloxy- and piperidinyloxybenzylamides and related compounds as modulators of melanin concentrating hormone (MCH1) receptor modulators. WO 2007/ 078251, 2007.
220. Takekawa, S.; Asami, A.; Ishihara, Y.; Terauchi, J.; Kato, K.; Shimomura, Y.; Mori, M.; Murakoshi, H.; Kato, K.; Suzuki, N.; Nishimura, O.; Fujino, M. T-226296: A novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur. J. Pharmacol. 2002, 438, 129-135.
221. Kowalski, T.J.; Farley, C.; Cohen-Williams, M.E.; Varty, G.; Spar, B.D. Melanin-concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size. Eur. J. Pharmacol. 2004, 497, 41-47.
222. Meyers, K.M.; Kim, N.; Mendez-Andino, J.L.; Hu, X.E.; Mumin, R.N.; Klopfenstein, S.R.; Wos, J.A.; Mitchell, M.C.; Paris, J.L.; Ackley, D.C.; Holbert, J.K.; Mittelstadt, S.W.; Reizes, O. Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists-Increasing selectivity over hERG. Bioorg. Med. Chem. Lett. 2007, 17, 814-818.
223. Hu, X.E.; Wos, J.A.; Dowty, M.E.; Suchanek,. P.M.; Ji, W.; Chambers, J.B.; Benoit, S.C.; Clegg, D.J.; Reizes, O. Small-molecule melanin-concentrating hormone-1 receptor antagonists require brain penetration for inhibition of food intake and reduction in body weight. J. Pharmacol. Exp. Ther. 2008, 324, 206-213.
224. Warshakoon, N.C.; Sheville, J.; Bhatt, R.T.; Ji, W.; Mendez-Andino, J.L.; Meyers, K.M.; Kim, N.; Wos, J.A.; Mitchell, C.; Paris, J.L.; Pinney, B.B.; Reizes, O.; Hu, X.E. Design and synthesis of substituted quinolines as novel and selective melanin concentrating hormone antagonists as anti-obesity agents. Bioorg. Med. Chem. Lett. 2006, 16, 5207-5211.
225. Grey, J.; Dyck, B.; Rowbottom, M.W.; Tamiya, J.; Vickers, T.D.; Zhang, M.; Zhao, L.; Heise, C.E.; Schwarz, D.; Saunders, J.; Goodfellow, V.S. Bis(aminopyrrolidine)-derived ureas (APUs) as potent MCH1 receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 999-1004.
226. Rowbottom, M.W.; Vickers, T.D.; Dyck, B.; Tamiya, J.; Zhang, M.; Zhao, L.; Grey, J.; Provencal, D.; Schwarz, D.; Heise, C.E.; Mistry, M.; Fisher, A.; Dong, T.; Hu, T.; Saunders, J.; Goodfellow, V.S. Synthesis and structure-activity relationships of biarylcarboxamide bis-aminopyrrolidine urea derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Bioorg. Med. Chem. Lett. 2005, 15, 3439-3445.
227. Hudson, S.; Kiankarimi, M.; Rowbottom, M.W.; Vickers, T.D.; Wu, D.; Pontillo, J.; Ching, B.; Dwight, W.; Goodfellow, V.S.; Schwarz, D.; Heise, C.E.; Madan, A.; Wen, J.; Ban, W.; Wang, H.; Wade, W.S. Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2. Bioorg. Med. Chem. Lett. 2006, 16, 4922-4930.
228. Stenkamp, D.; Lehmann-Lintz, T.; Mueller, S.; Rudolf, K.; Lustenberger, P.; Arndt, K.; Lotz, R.; Wieland, H.; Lenter, M. Preparation of arylquinoazolinones and related compounds as melanin concentrating hormone (MCH) antagonists. WO2004/024702 2004.
229. Goodfellow, V.; Dyck, B.P.; Zhao, L.; Tamiya, J.; Grey, J.; Wade, W.; Rowbottom, M.; Zhang, M.; Vickers, D. Preparation of aminopyrrolidinyl pyridines as MCH receptor antagonists. WO 2005/103039, 2005.
230. Zhang, M.; Tamiya, J.; Nguyen, L.; Rowbottom, M.W.; Dyck, B.; Vickers, T. D.; Grey, J.; Schwarz, D.A.; Heise, C.E.; Haelewyn, J.; Mistry, M.S.; Goodfellow, V.S. Thienopyrimidinone bisaminopyrrolidine ureas as potent melanin-concentrating hormone receptor-1 (MCH-R1) antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 2535-2539.
231. Amegadzie, A.K.; Beck, J.P.R; Gardinier, K.M.; Hembre, E.J.; Ruble, J.C.; Savin, K.A.; Wakefield, B.D. Preparation of thiazolopyridinones as MCH receptor antagonists for treating and preventing symptoms associated with obesity and related diseases. WO 2006/066174, 2006.
232. Arnold, M.B.; Dao, Y.; Gardinier, K.M.; Garmene, D. J.; Green, S.J.; Hembre, E.J.; Lu, J. Thienopyridines as melanin-concentrating hormone receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. WO 2007/146758, 2007.
233. Amegadzie, A.K.; Dao, Y.; Gardinier, K.M.; Garmene, D.J.; Green, S.J.; Hembre, E.J.; Lu, J.; Spinazze, P.G. Preparation of thieno[2,3-c]pyridine derivatives as MCH receptor antagonists. WO 2007/ 146759, 2007.
234. Gardinier, K.M.; Garmene, D.J.; Hembre, E.J.; Brunavs, M.; Szekeres, H.J. Thiazolopyridinone derivatives as MCH receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of obesity. WO 2008/076562, 2008.
235. Murata, T.; Makino, S. Preparation of thieno[3,2-d]pyrimidone compounds as melanin-concentrating hormone receptor antagonists. WO 2006/ 118320, 2006.
236. Giordanetto, F.; Inghardt, T.; Nordberg, P. Preparation of thieno [3,2-d]pyrimidin-4(3H)-one derivatives as MCH antagonists. WO 2007/011284, 2007.
237. Giordanetto, F.; Inghardt, T. Benzimidazolyl-substituted thienoheterocycles, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of obesity, psychiatric and neurological disorders. WO 2007/011285, 2007.
238. Giordanetto, F.; Inghardt, T. Thienoheterocycles, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of obesity, psychiatric and neurological disorders. WO 2007/011286, 2007.
239. Giordanetto, F.; Inghardt, T. Thienopyrimidinone derivatives as MCHr1 antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2008/020799, 2008.
240. Ahmad, S.; Ngu, K.; Washburn, W.N. Preparation of thienopyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists. WO 2007/ 050723, 2007.
241. Zhao, G. 3,4-Dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as melanin concentrating hormone receptor-1 antagonists and their preparation, pharmaceutical compositions and use in the treatment of disease. WO 2007/092416), 2007.
242. Guo, T.; Hunter, R.C.; Zhang, R.; Greenlee, W.J. Microwave-assisted synthesis of isothiazolo-, thiazolo-, imidazo-, and pyrimido-pyrimidinones as novel MCH1R antagonists. Tetrahedron 2007, 48, 613-615.
243. Dyck, B.; Markison, S.; Zhao, L.; Tamiya, J.; Grey, J.; Rowbottom, M.W.; Zhang, M.; Vickers, T.; Sorensen, K.; Norton, C.; Wen, J.; Heise, C.E.; Saunders, J.; Conlon, P.; Madan, A.; Schwarz, D.; Goodfellow, V.S. A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties. J. Med. Chem. 2006, 49, 3753-3756.
244. Dyck, B.; Zhao, L.; Tamiya, Ju.; Pontillo, J.; Hudson, S.; Ching, B.; Heise, C. E.; Wen, J.; Norton, C.; Madan, A.; Schwarz, D.; Wade, W.; Goodfellow, V.S. Substituted chromones and quinolones as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 4237-4242.
245. Mueller, S.-G.; Stenkamp, D.; Arndt, K.; Roth, G.J.; Lotz, R.R.H.; Lehmann-Lintz, T.; Lenter, M.; Lustenberger, P.; Rudolf, K. Preparation of ethynylpyridines and related compounds as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders. WO 2004/039780, 2004.
246. Stenkamp, D.; Mueller, S.G.; Lustenberger, P.; Lehmann-Lintz, T.; Roth, G.J.; Rudolf, K.; Schindler, M.; Thomas, L.; Lotz, R.R.H. Preparation of alkynyl benzopyran derivatives as MCH receptor antagonists. WO 2005/ 100285, 2005.
247. Stenkamp, D.; Mueller, S.G.; Lustenberger, P.; Lehmann-Lintz, T.; Roth, G.J.; Rudolf, K.; Schindler, M.; Thomas, L.; Lotz, R. Preparation of substituted pyridine alkynes with MCH antagonistic activity for the treatment of metabolic disorders. WO 2005/103002, 2005.
248. Stenkamp, D.; Mueller, S.G.; Lehmann-Lintz, T.; Lustenberger, P.; Thomas, L.; Schindler, M.; Roth, G.J.; Rudolf, K.; Lotz, R.R.H. Preparation of alkynyl quinoline derivatives as MCH receptor antagonists. WO 2005/103029, 2005.
249. Stenkamp, D.; Mueller, S.G.; Lehman-Lintz, T.; Thomas, L.; Schindler, M.; Roth, G.J.; Rudolf, K.; Lotz, R.R. Diarylalkyne compounds with MCH-receptor antagonistic activity, their preparation, pharmaceutical compositions, and use in therapy. WO 2005/103031, 2005.
250. Stenkamp, D.; Mueller, S.G.; Lustenberger, P.; Lehmann-Lintz, T.; Roth, G.J.; Schindler, M.; Thomas, L.; Lotz, R.R.H.; Rudolf, K. Preparation of alkynyl pyridine derivatives as MCH receptor antagonists. WO 2005/ 103032, 2005.
251. Lehmann-Lintz, T.; Lustenberger, P.; Roth, G.J.; Schindler, M.; Thomas, L.; Mueller, S.G.; Stenkamp, D.; Lotz, R.R.H.; Rudolf, K. Preparation of 3-(4-piperidin-1-ylmethylphenyl)propionic acid phenylamides and related compounds used as MCH-1R antagonists (MCH = melanin concentrating hormone) for treating eating disorders. WO 2005/063239, 2005.
252. Roth, G.J.; Mueller, S.G.; Lehmann-Lintz, T.; Stenkamp, D.; Lustenberger, P.; Kley, J.; Rudolf, K.; Heckel, A.; Schindler, M.; Thomas, L.; Lotz, R.R.H. (Hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds and their preparation and use in the treatment of metabolic and eating disorders. WO 2007/048802, 2007.
253. Schwink, L.; Stengelin, S.; Gossel, M.; Boehme, T.; Hessler, G.; Stahl, P.; Gretzke, D. Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists. WO 2004/072025, 2004.
254. Schwink, L.; Stengelin, S.; Gossel, M.; Hessler, G.; Lennig, P. Preparation of 2,7-diazabicyclo[3.3.0]octanes and related compounds as antiobesity agents. WO 2006/018280, 2006.
255. Schwink, L.; Stengelin, S.; Gossel, M.; Hessler, G.; Haack, T.; Lennig, P. Preparation of azacyclyl-substituted arylthienopyrimidinones as melanin concentrating hormone receptor type I (MCH1R) antagonists. WO 2007/093363, 2007.
256. Schwink, L.; Stengelin, S.; Gossel, M.; Hessler, G.; Haack, T.; Lennig, P. Azacyclyl-substituted aryldihydroisoquinolinones as MCH antagonists, process for their preparation and their use as medicaments. WO 2007/ 093364, 2007.
257. Schwink, L.; Stengelin, S.; Gossel, M.; Hessler, G.; Haack, T.; Lennig, P. Preparation of novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments. WO 2007/093365, 2007.
258. Schwink, L.; Stengelin, S.; Gossel, M. Preparation of indol-5-ylureas and relate compounds for the treatment of obesity and type II diabetes. WO 2003/015769, 2003.
259. Schwink, L.; Stengelin, S.; Gossel, M; Boehme, T; Hessler, G; Rosse, G; Walser, A. Preparation of 1,3-dihydro-1,3-diphenyl-2H-imidazol-2-ones and related compounds as MCH receptor modulators for the treatment of obesity. WO 2004/012648, 2004.
260. Schwink, L.; Boehme, T.; Gossel, M.; Stengelin, S. Preparation of N-cyclohexylimidazolinones as MCH receptor modulators. WO 2005/ 070898, 2005.
261. Souers, A.J.; Collins, C.A.; Gao, J.; Judd, A.S.; Kym, P.R.; Mulhern, M.M.; Sham, H.L.; Vasudevan, A.; Wodka, D. Preparation of N-indazolylalkanamide and N-indazolylurea derivatives as antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor. US 2005/137243, 2005.
262. Souers, A.J.; Collins, C.A.; Gao, J.; Judd, A.S.; Kym, P.R.; Mulhern, M.M.; Sham, H.L.; Wodka, D. Preparation of substituted 2H-indazoles as antagonists of the melanin concentrating hormone receptor for eating disorders. US 2005/187279, 2005.
263. Brown, D.; Blackwell, W.C.; Mclaren, F.M.; Schnecke, V.; Smith, R.W.; Steelman, G.; Wang, X.; Urbanek, R.A.; Wesolowski, S. Preparation of heterocyclic amides as novel MCHR1 antagonists and their use for treatment of MCHR1 mediated conditions and disorders. WO 2006/130075, 2006.
264. Balavoine, F.; Nicolaie, E.; Sartori, E. Preparation of hydantoin derivatives and their use as MCHR-1 antagonists. WO 2007/012661, 2007.
265. Balavoine, F.; Nicolaie, E.; Sartori, E. Preparation of 5- benzylideneimidazolidine-2,4-dione derivatives and their use as MCHR-1 antagonists. WO 2007/012670, 2007.
266. Hoegberg, T.; Bjurling, A.E.; Receveur, J.-M.; Little, P.B.; Elling, C.E.; Norregaard, P.K.; Ulven, T. Preparation of novel methoxybenzamides for use in MCH receptor related disorders. WO 2003/087045, 2003.
267. Souers, A.J.; Gao, J.; Wodka, D.; Judd, A.S.; Mulhern, M.M.; Napier, J.J.; Brune, M.E.; Bush, E.N.; Brodjian, S.J.; Dayton, B.D.; Shapiro, R.; Hernandez, L.E.; Marsh, K.C.; Sham, H.L.; Collins, C.A.; Kym, P.R. Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 2005, 15, 2752-2757.
268. Alavoine, F.; Malabre, P.; Alleaume, T.; Rey, A.; Cherfils, V.; Jeanneton, O.; Seigneurin-Venin, S.; Revah, F. Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 3754-3759.
269. Eceveur, J.-M.; Bjurling, E.; Ulven, T.; Little, P.B.; Norregaard, P.K.; Hoegberg, T. 4-Acylamino- and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 5075-5080.
270. Chen, X.; Dai, K.; Fan, P.; Huang, S.; Li, L.; Mihalic, J.T. Preparation of fused indole derivatives as MCHR modulators for treatment of obesity. WO 2002/089729, 2002.
271. Chen, X.; Dai, K.; Fan, P.; Fu, Y.; Li, L.; Mihalic, J.T. Preparation of piperidinylmethyl carbazole derivatives as MCHR modulators. WO 2004/ 028459, 2004.
272. Chen, X.; Chen, X.; Fan, P.; Jaen, J.; Li, L.; Mihalic, J.T. Preparation of pyrido[4,3-b]carbazole as G-protein coupled receptor modulators for treatment of eating disorders. WO 2004/043958, 2004.
273. Hulme, C.; Tempest, P.; Ma, V.; Nixey, T.; Balow, G. Preparation of tetrazolylmethylpiperazines as melanin concentrating hormone receptor antagonists. WO 2005/019167, 2005.
274. Tempest, P.; Hulme, C.; Ma, V. Amine-containing phenyl derivative melanin-concentrating hormone receptor antagonists for therapeutic use. WO 2005/019240, 2005.
275. Ma, V.; Bannon, A. W.; Baumgartner, J.; Hale, C.; Hsieh, F.; Hulme, C.; Rorrer, K.; Salon, J.; van Staden, C.; Tempest, P. Solid-phase synthesis and structure-activity relationships of novel biarylethers as melanin-concentrating hormone receptor-1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 5066-5072.
276. McBriar, M.D.; Palani, A.; Shapiro, S.A.; Xu, R.; Clader, J. Preparation of substituted ureas as MCH antagonists useful in the treatment of obesity. WO 2002/057233, 2002.
277. Clader, J. W.; Josien, H.B.; Palani, A.; Chan, T.-Y. Preparation of N-[biaryl(piperidinyl)ethyl]-N'-arylureas and analogs as melanin-concentrating hormone receptor antagonists. WO 2002/076947, 2002.
278. Hobbs, D.W.; Guo, T.; Hunter, R.C.; Gu, H. Preparation of aryl and biaryl derivatives having melanin-concentrating hormone modulatory activity. WO 2002/076929, 2002.
279. Hobbs, D.W.; Guo, T.; Hunter, R.C.; Gu, H.; Babu, S.D.; Shao, Y.
280. Palani, A.; Shapiro, S.A.; McBriar, M.D.; Su, J. Preparation of substituted aromatic amide MCH antagonists for the treatment of obesity. WO 2003/035055, 2003.
281. Burnett, D.A.; Wu, W.-L. Preparation of piperidine-based MCH antagonists for treatment of obesity and CNS disorders. WO 2003/045918, 2003.
282. Clader, J.W.; Palani, A.; Xu, R.; McBriar, M.D.; Su, J.; Tang, H. Preparation of N-aryl-N'-arylcycloalkyl-urea derivatives as MCH antagonists for the treatment of obesity. WO 2003/047568, 2003.
283. Eulenberg, K.; Steuernagel, A.; Haeder, T.; Meise, M.; Broenner, G. Proteins involved in the regulation of energy homeostasis and uses for diagnosis and treatment of obesity and/or diabetes. WO 2003/092715, 2003.
284. Burnett, D.A.; Wu, W.-L.; Sasikumar, T.K.; Domalski, M.S. Preparation of spiro substituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity. WO 2004/002987, 2004.
285. Sasikumar, T.K.; Wu, W.-L.; Burnett, D.A.; Qiang, L. Preparation of diarylpiperidinyltetrahydroisoquinolines as selective melanin concentrating hormone (MCH) receptor antagonists for the treatment of obesity and related disorders. WO 2004/078745, 2004.
286. Palani, A.; Shapiro, S.A.; Josien, H.B.; Bara, T.A.; Clader, J.W.; Pushpavanam, P.B.; Li, S.; Mcbriar, M.D. A preparation of pyrazine derivatives, useful as MCH antagonists. WO 2005/005419, 2005.
287. Wu, W.-L.; Burnett, D.A.; Caplen, M.A. Preparation of biaryl piperidinylidenemethyl benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders. WO 2005/021528, 2005.
288. Burnett, D.A.; Wu, W.-L.; Sasikumar, T.K.; Greenlee, W.J.; Caplen, M.A.; Guo, T.; Hunter, R.C. Preparation of 2-substituted benzimidazole piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders. WO 2005/ 023798, 2005.
289. Sasikumar, T.K.; Burnett, D.A. Preparation of aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders. WO 2005/034947, 2005.
290. Su, J.; McKittrick, B.; Tang, H.; Sasikumar, T.K.; Qiang, L. Preparation of heterocyclyls as selective MCH receptor antagonists for the treatment of obesity. WO 2006/019957, 2006.
291. Guo, T.; Gu, H.; Hobbs, D.W.; Busler, D.E., Rokosz, C.L. Discovery of tetralin ureas as potent melanin concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 1718-1721
292. Wu, W.-L.; Burnett, D.A.; Spring, R.; Qiang, L.; Sasikumar, T.K.; Domalski, M.S.; Greenlee, W.J.; O'Neill, K.; Hawes, B.E. Synthesis and structure-activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 3668-3673.
293. McBriar, M.D.; Guzik, H.; Shapiro, S.; Xu, R.; Paruchova, J.; Clader, J.W.; O'Neill, K.; Hawes, B.; Sorota, S.; Margulis, M.; Tucker, K.; Weston, D.J.; Cox, K. Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 antagonists: Impacting hERG liability via aryl modifications. Bioorg. Med. Chem. Lett. 2006, 16, 4262-4265.
294. Su, J.; Tang, H.; McKittrick, B.A.; Gu, H.; Guo, T.; Qian, G.; Burnett, D.A.; Clader, J.W.; Greenlee, W.J.; Hawes, B.E.; O'Neill, K.; Spar, B.; Weig, B.; Kowalski, T.; Sorota, S. Synthesis of novel bicyclo[4.1.0]heptane and bicyclo[3.1.0]hexane derivatives as melanin-concentrating hormone receptor R1 antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 4845-4850.
295. McBriar, M.D.; Guzik, H.; Xu, R.; Paruchova, J.; Li, S.; Palani, A.; Clader, J.W.; Greenlee, W.J.; Hawes, B.E.; Kowalski, T.J.; O'Neill, K.; Spar, B.; Weig, B. Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: Orally efficacious antiobesity therapeutics. J. Med. Chem. 2005, 48, 2274-2277
296. Guo, T.; Hunter, R.C.; Gu, H.; Rokosz, L.L.; Stauffer, T.M.; Hobbs, D.W. Discovery and SAR of 4-amino-2-biarylbutylurea MCH 1 receptor antagonists through solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. 2005, 15, 3691-3695.
297. Guo, T.; Shao, Y.; Qian, G.; Rokosz, L.L.; Stauffer, T.M.; Hunter, R.C.; Babu, S.D.; Gu, H.; Hobbs, D.W. Discovery and SAR of biaryl piperidine MCH1 receptor antagonists through solid-phase encoded combinatorial synthesis. Bioorg. Med. Chem. Lett. 2005, 15, 3696-3700.
298. Palani, A.; Shapiro, S.; McBriar, M.D.; Clader, J.W.; Greenlee, W.J.; O'Neill, K.; Hawes, B. Biaryl diamides as potent melanin concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 5234-5236.
299. McBriar, M.D.; Guzik, H.; Shapiro, S.; Paruchova, J.; Xu, R.; Palani, A.; Clader, J.W.; Cox, K.; Greenlee, W.J.; Hawes, B.E.; Kowalski, T.J.; O'Neill, K.; Spar, B.D.; Weig, B.; Weston, D.J..; Farley, C.; Cook, J. Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas. J. Med. Chem. 2006, 49, 2294-2310.
300. Wu, W.-L.; Burnett, D.A.; Spring, R.; Qiang, L.; Sasikumar, T.K.; Domalski, M.S.; Greenlee, W.J.; O'Neill, K.; Hawes, B.E. Synthesis and structure-activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 3668-3673.
301. Wu, W.-L.; Burnett, D.A.; Caplen, M.A.; Domalski, M.S.; Bennett, C.; Greenlee, W.J.; Hawes, B.E.; O'Neill, K.; Weig, B.; Weston, D.; Spar, B.; Kowalski, T. Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 3674-3678.
302. Sasikumar, T.K.; Qiang, L.; Wu, W.-L.; Burnett, D.A.; Greenlee, W.J.; O'Neill, K.; Hawes, B.E.; van Heek, M.; Graziano, M. Tetrahydroisoquinolines as MCH-R1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 4917-4921.
303. Sasikumar, T.K.; Li, Q.; Burnett, D.A.; Greenlee, W.J.; Hawes, B.E.; Kowalski, T.J.; O'Neill, K.; Spar, B.D.; Weig, B. Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases. Bioorg. Med. Chem. Lett. 2006, 16, 5427-5431.
304. Guo, T.; Gu, H.; Hobbs, D.W.; Busler, D.E.; Rokosz, L.L. Discovery of tetralin ureas as potent melanin concentrating hormone 1 receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 1718-1721.
305. Su, J.; McKittrick, B.A.; Tang, H.; Burnett, D.A.; Clader, J.W.; Greenlee, W.J.; Hawes, B.E.; O'Neill, K.; Spar, B.; Weig, B.; Kowalski, T.; Sorota, S.; Li, C.; Liu, T. SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: Taming hERG. Bioorg. Med. Chem. 2007, 15, 5369-5385.
306. Vasudevan, A.; Verzal, M.K.; Wodka, D.; Souers, A.J.; Blackburn, C.; Che, J.L.; Lai, S.; Brodjian, S.; Falls, D.H.; Dayton, B.D.; Govek, E.; Daniels, T.; Geddes, B.; Marsh, K.C.; Hernandez, L.E.; Collins, C.A.; Kym, P.R. Identification of aminopiperidine benzamides as MCHr1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 3412-3416.
307. Vasudevan, A.; LaMarche, M.J.; Blackburn, C.; Che, J.L.; Luchaco-Cullis, C.A.; Lai, S.; Marsilje, T.H.; Patane, M.A.; Souers, A. J.; Wodka, D.; Geddes, B.; Chen, S.; Brodjian, S.; Falls, D.H.; Dayton, B.D.; Bush, E.; Brune, M.; Shapiro, R.D.; Marsh, K.C.; Hernandez, L.E.; Sham, H.L.; Collins, C.A.; Kym, P.R. Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 4174-4179.
308. Vasudevan, A.; Souers, A.J.; Freeman, J.C.; Verzal, M.K.; Gao, J.; Mulhern, M.M.; Wodka, D.; Lynch, J.K.; Engstrom, K.M.; Wagaw, S.H.; Brodjian, S.; Dayton, B.; Falls, D.H.; Bush, E.; Brune, M.; Shapiro, R.D.; Marsh, K.C.; Hernandez, L.E.; Collins, C.A.; Kym, P.R. Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 5293-5297.
309. Blackburn, C.; Lai, S.-J.; Lee, J.G.; Maguire, M.; Patane, M.A.; Lamarche, M.J.; Cullis, C.A.; Brown, J.; Vasudevan, A.; Freeman, J.C.; Mulhern, M.M.; Lynch, J.K.; Gao, J.; Wodka, D.; Souers, A.J.; Iyengar, R. Preparation of coumarin, quinolone, quinazolinone and related compounds as antagonists of melanin concentrating hormone receptor-1 for treating disorders like obesity. WO 2003/106452 A2, 2003.
310. Lynch, J.K.; Freeman, J.C.; Judd, A.S.; Iyengar, R.; Mulhern, M.; Zhao, G.; Napier, J.J.; Wodka, D.; Brodjian, S.; Dayton, B.D.; Falls, D.; Ogiela, C.; Reilly, R.M.; Campbell, T.J.; Polakowski, J.S.; Hernandez, L.; Marsh, K.C.; Shapiro, R.; Knourek-Segel, V.; Droz, B.; Bush, E.; Brune, M.; Preusser, L.C.; Fryer, R.M.; Reinhart, G.A.; Houseman, K.; Diaz, G.; Mikhail, A.; Limberis, J.T.; Sham, H.L.; Collins, C.A.; Kym, P.R. Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: Assessment of potency, efficacy, and cardiovascular safety. J. Med. Chem. 2006, 49, 6569-6584.
311. Lynch, J.K.; Collins, C.A.; Freeman, J.C.; Gao, J.; Iyengar, R.R.; Judd, A.S.; Kym, P.R.; Mulhern, M.M.; Sham, H.L.; Souers, A.J.; Zhao, G.; Wodka, D. Preparation of piperidinyl chromene-carboxamides as antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor. US 2005/209274, 2005.
312. Iyengar, R.R.; Lynch, J.K.; Mulhern, M.M.; Judd, A.S.; Freeman, J.C.; Gao, J.; Souers, A.J.; Zhao, G.; Wodka, D.; Falls, H.D.; Brodjian, S.; Dayton, B.D.; Reilly, R.M.; Swanson, S.; Su, Z.; Martin, R.L.; Leitza, S.T.; Houseman, K.A.; Diaz, G.; Collins, C.A.; Sham, H.L.; Kym, P.R. An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 874-878.
313. Souers, A.J.; Ivengar, R.R.; Judd, A.S.; Beno, D.W.; Gao, J.; Zhao, G.; Brune, M.E.; Napier, J.J.; Mulhern, M.M.; Lynch, J.K.; Freeman, J.C.; Wodka, D.; Chen, C.J.; Falls, H.D.; Brodjian, S.; Dayton, B.D.; Diaz, G.J.; Bush, E.N.; Shapiro, R.; Droz, B.A.; Knourek-Segel, V.; Hernandez, L.E.; Marsh, K.C.; Reilly, R.M.; Sham, H.L.; Collins, C.A.; Kym, P.R. Constrained 7-fluorocarboxychromone-4-aminopiperidine based melanin-concentrating hormone receptor-1 antagonist: The effects of chirality on substituted indan-1-ylamines. Bioorg. Med. Chem. Lett. 2007, 17, 884-889.
314. Kym, P.R.; Iyengar, R.; Souers, A.J.; Lynch, J.K.; Judd, A.J.; Gao, J.; Freeman, J.; Mulhern, M.; Zhao, G.; Vasudevan, A.; Wodka, D.; Blackburn, C.; Brown, J.; Che, J.L.; Cullis, C.; Lai, S.J.; LaMarche, M.; Marsilje, T.; Roses, J.; Sells, T.; Geddes, B.; Govek, E.; Patane, M.; Fry, D.; Dayton, B.D.; Brodjian, S.; Falls, D.; Brune, M.; Bush, E.; Shapiro, R.; Knourek-Segel, V.; Fey, T.; McDowell, C.; Reinhart, G.A.; Preusser, L.C.; Marsh, K.; Hernandez, L.; Sham, H.L.; Collins, C.A. Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists. J. Med. Chem. 2005, 48, 5888-5891.
315. Kym, P.R.; Souers, A.J.; Campbell, T.J.; Lynch, J.K.; Judd, A.S.; Iyengar, R.; Vasudevan, A.; Gao, J.; Freeman, J.C.; Wodka, D.; Mulhern, M.; Zhao, G.; Wagaw, S.H.; Napier, J.J.; Brodjian, S.; Dayton, B.D.; Reilly, R.M.; Segreti, J.A.; Fryer, R.M.; Preusser, L.C.; Reinhart, G.A.; Hernandez, L.; Marsh, K.C.; Sham, H.L.; Collins, C.A.; Polakowski, J.S. Screening for cardiovascular safety: A structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J. Med. Chem. 2006, 49, 2339-2352
316. Souers, A.J.; Iyengar, R.R.; Judd, A.S.; Beno, D.W. A.; Gao, J.; Zhao, G.; Brune, M.E.; Napier, J.J.; Mulhern, M.M.; Lynch, J.K.; Freeman, J.C.; Wodka, D.; Chen, C.J.; Falls, H.D.; Brodjian, S.; Dayton, B.D.; Diaz, G.J.; Bush, E.N.; Shapiro, R.; Droz, B.A.; Knourek-Segel, V.; Hernandez, L.E.; Marsh, K.C.; Reilly, R.M.; Sham, H.L.; Collins, C.A.; Kym, P.R. Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: The effects of chirality on substituted indan-1-ylamines. Bioorg. Med. Chem. Lett. 2007, 17, 884-889.
317. Augereau, J.M.; Geslin, M. Preparation of 1-aminophthalazine derivatives as melanin concentrating hormone receptor (MCHR), particularly MCH-1R, antagonists. FR 2868780, 2005.
318. Augereau, J.M.; Courtemanche, G.; Geslin, M.; Serva, L. Preparation of 1-aminophthalazine derivatives as melanin concentrating hormone receptor (MCHR), particularly MCH-1R, antagonists. WO 2007/042660, 2007.
319. Augereau, J.M.; Courtemanche, G.; Geslin, M. Preparation of 1-aminoisoquinoline derivatives as melanin concentrating hormone receptor (MCHR), particularly MCH-1R, antagonists. WO 2007/042668, 2007.
320. Augereau, J.M.; Courtemanche, G.; Despeyroux, P.; Geslin, M.; Thomas, A. Preparation of 4-aminoquinazoline derivatives as melanin concentrating hormone receptor (MCHR), particularly MCH-1R, antagonists. WO 2007/ 042669, 2007.
321. Brickmann, K.; Egner, B.J.; Giordanetto, F.; Inghardt, T.; Linusson Jonsson, A.; Ponten, F. Preparation of 4-amido-N-substituted piperidine derivatives as CCR3 modulators and melanin concentrating hormone receptor 1 (MCH1r) ligands. WO 2005/090330, 2005.
322. Egner, B.; Giordanetto, F.; Inghardt, T. Preparation of heterocycles as melanin concentrating hormone receptor 1 (MCHR1) antagonists. WO 2006/ 068594, 2006.
323. Kim, N.; Meyers, K.M.; Mendez-Andino, J.L.; Warshakoon, N.C.; Ji, W.; Wos, J.A.; Colson, A.; Mitchell, M.C.; Davis, J.R.; Pinney, B.B.; Reizes, O.; Hu, X.E. Identification of substituted 4-aminopiperidines and 3-aminopyrrolidines as potent MCH-R1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 2006, 16, 5445-5450.
324. Kaku, H.; Kondoh, Y.; Hayashibe, S.; Kamikubo, T.; Iwasaki, F.; Matsumoto, S.; Kimura, Y.; Kurama, T. Preparation of piperidines and related compounds as melanin-concentrating hormone receptor antagonist for treatment of obesity. WO 2004/046110, 2004.
325. Kako, H.; Iwasaki, S.; Iikubo, K.; Moritomo, H.; Kimura, T.; Suwa, A. Preparation of 1-cinnamylpiperidine derivatives as melanin concentrating hormone (MCH) receptor antagonists. JP 2005/325031, 2005.
326. Kym, P.R.; Hartandi, K.; Gao, J.; Phelan, K.M.; Akritopoulou-Zanze, I.; Collins, C.A.; Vasudevan, A.; Verzal, M.K. Cis-N-(Quinolin -4-yl)cyclohexane-1,4-diamine derivatives as antagonists of melanin concentrating hormone (MCH) and their pharmaceutical compositions and therapeutic uses, e.g., for treatment of obesity. US 2003/229119, 2003.
327. Kanuma, K.; Omodera, K.; Nishiguchi, M.; Funakoshi, T.; Chaki, S.; Semple, G.; Tran, T.-A.; Kramer, B.; Hsu, D.; Casper, M.; Thomsen, B.; Sekiguchi, Y. Lead optimization of 4-(dimethylamino) quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg. Med. Chem. Lett. 2005, 15, 3853-3856.
328. Kanuma, K.; Omodera, K.; Nishiguchi, M.; Funakoshi, T.; Chaki, S.; Nagase, Y.; Iida, I.; Yamaguchi, J.-I.; Semple, G.; Tran, T.-A.; Sekiguchi, Y. Identification of 4-amino-2-cyclohexylamino-quinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. 2006, 14, 3307-3319.
329. Sekiguchi, Y.; Kanuma, K.; Omodera, K.; Busujima, T.; Tran, T.-A.; Han, S.D.; Casper, M.; Kramer, B.A. Preparation of novel quinazolines as MCH receptor antagonists. WO 2004/087680, 2004.
330. Sekiguchi, Y.; Kanuma, Y.; Omodera, K.; Tran, T.-A.; Kramer, B.A.; Beeley, N.R.A. Preparation of quinazoline-2,4-diamines as melanin concentrating hormone (MCH) receptor antagonists. JP 2004/315511, 2004.
331. Sekiguchi, Y.; Kanuma, K.; Omodera, K.; Busujima, T.; Tran, T.-A.; Han, S.D.; Casper, M.; Kramer, B.A. Preparation of novel quinazolines as MCH receptor antagonists. WO 2004/087680, 2004.
332. Sekiguchi, Y.; Kanuma, K.; Omodera, K.; Sato, K.; Hayashi, M.; Yamamoto, S. Preparation of pyridine derivatives as MCH receptor antagonists. WO 2006/035967, 2006.
333. Sekiguchi, Y.; Kanuma, Y.; Omodera, K.; Busujima, T.; Tran, T.-A.; Han, S..; Casper, M.; Brian, A.K.; Semple, G.; Zou, N. Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders. JP 2006/124387, 2006.
334. Sekiguchi, Y.; Kanuma, Y.; Omodera, K.; Tran, T.-A.; Semple, G.; Kramer, B.A. Preparation of pyrimidine derivatives as MCH receptor antagonists. JP 2007/091649, 2007.
335. Ray, A.K.; Sigfridsson, E.M.; Linusson, A.S.M.; Sandberg, P.M.; Inghardt, T.; Svensson, A.M.; Brickmann, K. Preparation of N-(cycloalkyl, aryl or heteroaryl)-N'-(quinolin-2-yl)alkyldiamines as melanin concentrating hormone receptor 1 (MCH1R) antagonists. WO 2004/004726, 2004.
336. Evertsson, E.; Inghardt, T.; Lindberg, J.; Linusson, A.; Giordanetto, F. Preparation of quinoline derivatives as MCH modulators. WO 2005/066132, 2005.
337. Evertsson, E.; Inghardt, T.; Lindberg, J.; Linusson, A. Preparation of substituted diaminoquinazolines as MCH1 receptor ligands for use in the treatment of neurological disorders. WO 2005/070902, 2005.
338. Giordanetto, F.; Karlsson, O.; Lindberg, J.; Larsson, L.-O.; Linusson, A.; Evertsson, E.; Morgan, D.G.A.; Inghardt, T. Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 4232-4241.
339. Kato, K.; Mori, M.; Suzuki, N.; Shimomura, Y.; Takekawa, S.; Choh, N. Preparation of diarylalakanediamine derivatives as melanin concentrating hormone (MCH) antagonists. WO 2001/021169, 2001.
340. Marzabadi, M.R.; Wetzel, J.; Deleon, J.E.; Jiang, Y. Preparation of substituted anilinic piperidines as MCH selective antagonists. WO 2003/ 004027, 2003.
341. Marzabadi, M.R.; Wetzel, J.D.; John, E.; Lagu, B.; Gluchowski, C.; Noble, S.; Nagarathnam, D. Preparation and use of arylpyrimidines as selective melanin concentrating hormone-1 (mch-1) receptor antagonists. US 2003/069261, 2003.
342. Marzabadi, M.R.; Wetzel, J.; Deleon, J.E.; Jiang, Y.; Chen, C.-A.; Lu, K. Preparation of substituted anilinic piperidines as MCH selective antagonists. US 6727264, 2004.
343. Marzabadi, M.; Jiang, A.; Lu, K.; Chen, C.-A.; Deleon, J.; Wetzel, J. Preparation of spirocyclic piperidines as selective MCH1 antagonists with therapeutic uses. WO 2004/004714, 2004.
344. Marzabadi, M.; Jiang, A.; Lu, K.; Chen, C.-A.; Deleon, J.; Wetzel, J. Preparation of secondary amino anilinic piperidines as selective MCH1 antagonists with therapeutic uses. WO 2004/005257, 2004.
345. Marzabadi, M.R.; Wetzel, J.M.; Chen, C.-A.; Jiang, Y.; Lu, K. Preparation of N-(piperidinylalkyl)benzenealkanamides as selective MCH1 receptor antagonists for treatment of obesity and other conditions. WO 2005/064764, 2004.
346. Marzabadi, M.R.; Wetzel, J.M.; Chen, C.-A.; Deleon, J.E.; Jiang, Y.; Lu, K. Preparation of 4-arylpiperidines as selective antagonists of melanin concentrating hormone-1 (MCH1) receptors. WO 2005/069834, 2005.
347. Marzabadi, M.R.; Jiang, Y.; Chen, C.-A.; Lu, K.; Andersen, K. Preparation of 1-(arylthiobenzyl)piperidine derivatives for treatment of depression and anxiety. WO 2006/041635, 2006.
348. Jiang, Y.; Chen, C.-A.; Lu, K.; Daniewska, I.; De Leon, J.; Kong, R.; Forray, C.; Li, B.; Hegde, L.G.; Wolinsky, T.D.; Craig, D.A.; Wetzel, J.M.; Andersen, K.; Marzabadi, M.R. Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 1. The discovery of arylacetamides as viable replacements for the dihydro-pyrimidinone moiety of an HTS hit. J. Med. Chem. 2007, 50, 3870-3882.
349. Marzabadi, M.R.; Chen, C.-A.; Jiang, Y.; Lu, K.; Andersen, K. Preparation of 1-(aryloxybenzyl)piperidine derivatives for treatment of depression and anxiety. WO 2006/041636, 2006.
350. Marzabadi, M.R.; Jiang, Y.; Chen, C.-A.; Lu, K.; Andersen, K. Preparation of 1-(arylthiobenzyl)piperidine derivatives for treatment of depression and anxiety. US 2006/079523, 2006.
351. Marzabadi, M.R.; Chen, C.-A.; Jiang, Y.; Lu, K.; Andersen, K. Preparation of 1-(aryloxybenzyl)piperidine derivatives for treatment of depression and anxiety. US 2006/079524, 2006.
352. Marzabadi, M.; Andersen, K.; Chen, B.; Reitman, M.; Jiang, Y.; Eldemenky, E. Preparation of alkylthiobenzylpiperidine compounds as MCH1 receptor ligands. WO 2007/114902, 2007.
353. Moriya, M.; Sakamoto, T.; Ishikawa, M.; Kanatani, A.; Fukami, T. Preparation of piperidine derivatives as melanin-concentrating hormone receptor antagonists. WO 2004/069798, 2004.
354. Suzuki, T.; Ando, M.; Miyazoe, H.; Kameda, M.; Sekino, E.; Moriya, M. Preparation of diaryl ketimine derivatives as antagonists of melanin concentrating hormone receptor. WO 2008/047544, 2008.
355. Chen, C.-A.; Jiang, Y.; Lu, K.; Daniewska, I.; Mazza, C.G.; Negron, L.; Forray, C.; Parola, T.; Li, B.; Hegde, L.G.; Wolinsky, T.D.; Craig, D.A.; Kong, R.; Wetzel, J.M.; Andersen, K.; Marzabadi, M.R. Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key fragments of HTS hits. J. Med. Chem. 2007, 50, 3883-3890.
356. Otake, N.; Haga, Y.; Naya, A.; Mizutani, S.; Kanatani, A. Preparation of pyridone and related compounds as melanin concentrating hormone receptor antagonists. WO 2005/085200, 2005.
357. Ando, M.; Sekino, E.; Haga, Y.; Otake, N.; Moriya, M. Preparation of 2-pyridone compounds as antagonists of melanin concentrating hormone receptor. WO 2007/018248, 2007.
358. Naya, A.; Sakamoto, T.; Haga, Y.; Otake, N. Preparation of phenylpyridone derivatives as MCH receptor antagonists. WO 2007/024004, 2007.
359. Sakuraba, S.; Kameda, M.; Kishino, H.; Haga, Y.; Otake, N.; Moriya, M. Preparation of pyridones containing bicyclic aromatic ring moiety as MCH receptor antagonists. WO 2007/029847, 2007.
360. Kishino, H.; Haga, Y.; Mizutani, S.; Moriya, M.; Otake, N. Preparation of 1-phenylpyridone derivatives as antagonists for melanin-concentrating hormone receptor. WO 2007/142217, 2007.
361. Alcazar-Vaca, M.J.; Andres-Gil, J.I.; Dautzenberg, F.M.; Macritchie, J.; Oyarzabal Santamarina, J. Novel N-aryl and N heteroaryl substituted pyridinone derivatives for use in MCH-1 mediated diseases and their preparation. WO 2007/141200, 2007.
362. Andres-Gil, J.I.; Alcazar-Vaca, M.J.; Dautzenberg, F.M.; Linders, J.T.M. Diazaspiropyridinone derivatives as MCH-1 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2008/068265, 2008.
363. Guzzo, P.; Surman, M.D.; Henderson, A.J.; Hadden, M.; Jiang, M.X. Preparation of 5-pyridinone substituted indazoles as modulators of melanin-concentrating hormone (MCH1) receptor. WO 2008/086404, 2008.
364. Guzzo, P.; Surman, M.D. Preparation of 5-furo[3,2-c] pyridinone substituted indazoles as modulators of melanin-concentrating hormone (MCH1) receptor. WO 2008/086409, 2008.
365. Armour, D.R.; Galan, S.R.G.; Lane, C.A.L.; Lansdell, M.I.; Mills, J.E.J.; Sciammetta, N.; Stupple, P.A. Pyridinone compounds as melanin concentrating hormone receptor-1 antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2008/041090, 2008.
366. Stenkamp, D.M.; Stephan G.; Lehmann-Lintz, T.; Roth, G.J.; Kley, J.; Rudolf, K.; Heckel, A.; Schindler, M.; Lotz, R. Preparation of pyridones as melanin concentrating hormone (MCH) receptor antagonists. WO 2008/ 022979, 2008.
367. da Silva, A.; Kuo, J.; Tallam, L.; Liu, J.; Hall, J. Does obesity induce resistance to the long-term cardiovascular and metabolic actions of melanocortin 3/4 receptor activation? Hypertension 2006, 47, 259-264.
368. Lynch, J.K.; Freeman, J.C.; Judd, A.S.; Iyengar, R.; Mulhern, M.; Zhao, G.; Napier, J.J.; Wodka, D.; Brodjian, S.; Dayton, B.D.; Falls, D.; Ogiela, C.; Reilly, R.M.; Campbell, T.J.; Polakowski, J.S.; Hernandez, L.; Marsh, K.C.; Shapiro, R.; Knourek-Segel, V.; Droz, B.; Bush, E.; Brune, M.; Preusser, L.C.; Fryer, R.M.; Reinhart, G.A.; Houseman, K.; Diaz, G.; Mikhail, A.; Limberis, J.T.; Sham, H.L.; Collins, C.A.; Kym, P.R. Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: Assessment of potency, efficacy and cardiovascular safety. J. Med. Chem. 2006, 49, 6569-6584.